#LCSM Transcript

Healthcare social media transcript of the #LCSM hashtag.
().
See #LCSM Influencers/Analytics.

Sign up for FREE Symplur Account and Get
  • Create Transcripts with Custom Dates
  • Get Custom Influencer Lists
  • 3x Hashtag Search Results
Sign Up Now
ProfileTweet
Brendon Stiles @BrendonStilesMD
Excited for everyone to be here. Yes it was #WCLC20 , but it was a great way to start 2021! #lcsm
Henning Willers, MD @HenningWillers
@HenningWillers #radonc #physicianscientist @MGHCancerCenter here, Trying to participate while fighting off kids (I might not win this one though ;-) ...) #lcsm
Nathan A. Pennell MD, PhD, FASCO @n8pennell
RT @JAMAOnc: The ADAURA trial showed an unprecedented improvement in DFS with adjuvant osimertinib in resected EGFR+ NSCLC, so is it time t…
Lung Cancer Sux @LungCancerSux
Glorianne from CT. Caregiver. Hubby is >10 years stage IV #LCSM
Brendon Stiles @BrendonStilesMD
#wclc20 was yet another great meeting from @iaslc. Certainly the best multidisciplinary meeting I am a part of. #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@BrendonStilesMD Hi everyone, joining in from Philly! Med Onc at @PennCancer. Good to see everyone! #LCSM
Brendon Stiles @BrendonStilesMD
I am tired of virtual meetings. I need to see, talk to, hug, laugh with friends, colleagues, and new acquaintances. I am sick of #COVID19. #lcsm
Stephen V Liu @StephenVLiu
RT @LungCancerFaces: ATTENTION #LCSM! Less than 30 minutes until #LCSM Chat. Please join moderator @BrendonStilesMD as he presents “#WCLC20
Brendon Stiles @BrendonStilesMD
That said….it has been a great year for lung cancer. This was obvious at #wclc20 #lcsm
Brendon Stiles @BrendonStilesMD
@CharuAggarwalMD @PennCancer Hi Charu! #lcsm
LungCancer.net @LungCancer_HU
Margot here! #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: I am tired of virtual meetings. I need to see, talk to, hug, laugh with friends, colleagues, and new acquaintances.…
K.B. @kbutler127
RT @lgreco_ny: Please share like your life depends on it. LIVES DO DEPEND ON IT. Churchill: Why won't New York vaccinate the vulnerable? #l
Faces of Lung Cancer @LungCancerFaces
Deana in Los Angeles here. I’ll be tweeting from the @lcsmchat account tonight. Join us now. https://t.co/WrClVC9owF #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@BrendonStilesMD Tremendous year! #LCSM
Brendon Stiles @BrendonStilesMD
For tonight’s chat: more info at https://t.co/Lx9qF406C9 #lcsm
caius kim @caiuskim
Caius here. #LCSM
Janet Freeman-Daily @JFreemanDaily
@BrendonStilesMD Amen. Ready for some in-person cameraderie! #LCSM
Watch Your Charts @watchyourcharts
@BrendonStilesMD QUESTION: Why there is no urgency to find cure for lung cancer by employing AI technology, expediting trials, pressuring scientists to find cure within 6-8 month deadline? My mom's life was already taken by cancer, it was a horrendous death. #LCSM
Brendon Stiles @BrendonStilesMD
You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm
Brendon Stiles @BrendonStilesMD
RT @JFreemanDaily: @BrendonStilesMD Amen. Ready for some in-person cameraderie! #LCSM
#LCSM Chat @lcsmchat
@LungCancer_HU Hey Margot! #lcsm
Janet Freeman-Daily @JFreemanDaily
Janet here from overcast Seattle. Glad to "see" my #LCSM tweeps again!
Brendon Stiles @BrendonStilesMD
To join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm or just follow along on regular twitter. #lcsm
#LCSM Chat @lcsmchat
@LungCancerSux Hey Glorianne! #lcsm
Jill Feldman @jillfeldman4
#WCLC20 is great because I could follow tweets/threads from @Jbauml @StephenVLiu @CharuAggarwalMD & others BUT I miss seeing everyone IRL #LCSM
Lisa Cunningham @LisaGemini
Me too! And I want the CCP punished!
Brendon Stiles @BrendonStilesMD
We'll get started in a few minutes -- please take a moment to introduce yourselves. #lcsm
Henning Willers, MD @HenningWillers
@BrendonStilesMD https://t.co/yIbKJBgfWO is also a good one #lcsm
#LCSM Chat @lcsmchat
@HenningWillers @MGHCancerCenter We’ll hope for the best. #lcsm
Alfonso J. Lopez @DrFonsi_
RT @CharuAggarwalMD: Capmatinib shows modest efficacy in patients with MET alterations treated with crizotinib Obj RR ~ 10% https://t.co/2…
Eric Bernicker @EricBernicker
Happy to be here. Eric, a thoracic medical oncologist from Houston. #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@jillfeldman4 @Jbauml @StephenVLiu Miss seeing you Jill, your talk was incredible! 🤗 #LCSM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: I am tired of virtual meetings. I need to see, talk to, hug, laugh with friends, colleagues, and new acquaintances.…
Brendon Stiles @BrendonStilesMD
@HenningWillers Indeed. tchat giving me trouble tonight! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: That said….it has been a great year for lung cancer. This was obvious at #wclc20 #lcsm
Janet Freeman-Daily @JFreemanDaily
@watchyourcharts @BrendonStilesMD Welcome to #LCSM Chat! Our chats are structured around specific questions. You can read tonight's topic questions here: https://t.co/g6Dul2e8Mw
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: For tonight’s chat: more info at https://t.co/Lx9qF406C9 #lcsm
Brendon Stiles @BrendonStilesMD
I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and patient advocate. Also still a bit pissed that my dad died from lung cancer. #LCSM https://t.co/nHFeKsKOXN
#LCSM Chat @lcsmchat
@caiuskim Welcome! Thanks for joining us. #lcsm
Deb Smith 🌻 @debsmithbeach
Deb from NH here. In Boston tonight, scans early tomorrow. #LCSM
Brendon Stiles @BrendonStilesMD
@MattSmeltzer Hi Matt! #lcsm
kristen kimball @KimballKristen
Kris here from Boston, hello! #LCSM
Dr. Marcos Galasso🇨🇦🇧🇷 @GalassoMarcos
RT @BrendonStilesMD: I am tired of virtual meetings. I need to see, talk to, hug, laugh with friends, colleagues, and new acquaintances.…
Brendon Stiles @BrendonStilesMD
I would like to disclose conflicts – I am the Board Chair of @lcrf_org & have worked with @astrazeneca @pfizer @bmsnews @genentech & others. These don’t affect opinions expressed tonight. #lcsm
#LCSM Chat @lcsmchat
@watchyourcharts @BrendonStilesMD We can certainly discuss this after tonight’s chat. I lost my mom to lung cancer, too. xo #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm
Brendon Stiles @BrendonStilesMD
In this week’s chat we hope to review some lung cancer highlights from #WCLC20 #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: To join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm or just follow along on regular twi…
Dave Bjork @bjork5
@BrendonStilesMD Hey @BrendonStilesMD sorry I’m late! Dave here joining from Boston 🙌 #LCSM
Lillian Leigh @ProjectBreath
Joining the conversation now - hello all #LCSM
#LCSM Chat @lcsmchat
RT @jillfeldman4: #WCLC20 is great because I could follow tweets/threads from @Jbauml @StephenVLiu @CharuAggarwalMD & others BUT I miss see…
Matthew Smeltzer @MattSmeltzer
Hi everyone! Matt from Memphis #LCSM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: We'll get started in a few minutes -- please take a moment to introduce yourselves. #lcsm
#LCSM Chat @lcsmchat
RT @HenningWillers: @BrendonStilesMD https://t.co/yIbKJBgfWO is also a good one #lcsm
#LCSM Chat @lcsmchat
@EricBernicker Yay! Welcome. #lcsm
Janet Freeman-Daily @JFreemanDaily
@SueMcCu30398663 Good to see you Sue! #LCSM
Laura Greco @lgreco_ny
Hello! Laura here. Greetings from upstate NY #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @watchyourcharts @BrendonStilesMD Welcome to #LCSM Chat! Our chats are structured around specific questions. You can r…
Brendon Stiles @BrendonStilesMD
@bjork5 Dave....my man. Thanks for joining! #LCSM If you haven't heard his podcasts, you are missing out!
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and patient advocate. Also still a bit pissed that…
Lillian Leigh @ProjectBreath
RT @BrendonStilesMD: I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and patient advocate. Also still a bit pissed that…
Dave Bjork @bjork5
@CharuAggarwalMD @BrendonStilesMD Hey Charu! #lcsm
Brendon Stiles @BrendonStilesMD
@ProjectBreath Hi Lillian! #lcsm
#LCSM Chat @lcsmchat
@debsmithbeach Best hopes, Deb. #lcsm
#LCSM Chat @lcsmchat
@KimballKristen Hey lady! #lcsm
Dave Bjork @bjork5
RT @jillfeldman4: #WCLC20 is great because I could follow tweets/threads from @Jbauml @StephenVLiu @CharuAggarwalMD & others BUT I miss see…
Brendon Stiles @BrendonStilesMD
#LungCancer led the way with newsworthy presentations. Great summary here from @StephenVLiu @NarjustDumaMD and Ross Soo #lcsm: https://t.co/xqRNI2ZpZT
Peggy Dennis @peggyddennis
#lcsm. Peggy joining a bit late from Denver
#LCSM Chat @lcsmchat
@ProjectBreath Woo HOO! Hello! #lcsm
Brendon Stiles @BrendonStilesMD
Here are t@APassaroMD top 5 presentations https://t.co/6iLv2xb3Bc #lcsm
Dave Bjork @bjork5
@debsmithbeach Good luck 🙏🏽 #lcsm
Jill Feldman @jillfeldman4
RT @BrendonStilesMD: #LungCancer led the way with newsworthy presentations. Great summary here from @StephenVLiu @NarjustDumaMD and Ross S…
#LCSM Chat @lcsmchat
@MattSmeltzer Welcome! #lcsm
Brendon Stiles @BrendonStilesMD
We will get started soon. First, a few reminders… #lcsm
ann price @aepriceny
@lcsmchat ann price here survivor, just retired this week, so I can enjoy my life--here to listen #lcsm
Brendon Stiles @BrendonStilesMD
Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat #lcsm
Dave Bjork @bjork5
@KimballKristen Boston is representing tonight! #LCSM
Henning Willers, MD @HenningWillers
@BrendonStilesMD hmmpf, as usual no #radonc advances (we need to do better) #lcsm
Janet Freeman-Daily @JFreemanDaily
Why do I get the feeling I'm not seeing all the tweets in #LCSM Chat? I see replies, but can't always see the original messages. **sigh**
Brendon Stiles @BrendonStilesMD
If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience #lcsm
Christine Qiong Wu @wi_qiong
@lgreco_ny Hi Laura #LCSM
#LCSM Chat @lcsmchat
@SueMcCu30398663 @JFreemanDaily Hi Sue! Remember to include #lcsm in your tweets and you’ll be just fine.
Brendon Stiles @BrendonStilesMD
I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to follow. #lcsm
Nathan A. Pennell MD, PhD, FASCO @n8pennell
Nate Pennell, oncologist in Cleveland! Hi all. #lcsm
Denise A Croix, PhD @CroixDenise
Hello! #LCSM
Lillian Leigh @ProjectBreath
@BrendonStilesMD Hello! Looking forward to today's #LCSM chat and to seeing you at tomorrow's @IASLC STARS!
#LCSM Chat @lcsmchat
@lgreco_ny Hey spitfire! #lcsm
mimiprovenzano @MimiProvenzano
Hi everybody, sorry I'm late! #LCSM
Brendon Stiles @BrendonStilesMD
We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. #lcsm
#LCSM Chat @lcsmchat
@peggyddennis Hi Peggy #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Here are t@APassaroMD top 5 presentations https://t.co/6iLv2xb3Bc #lcsm
Brendon Stiles @BrendonStilesMD
@HenningWillers Too many to describe! #lcsm
#LCSM Chat @lcsmchat
@aepriceny Hi Ann! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: We will get started soon. First, a few reminders… #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat #lcsm
kristen kimball @KimballKristen
@lcsmchat Hey there, Deana! #LCSM
Janet Freeman-Daily @JFreemanDaily
@HenningWillers @BrendonStilesMD We can't cover everything in one hour! I believe some #radonc advances were presented in the #STS conference on the same weekend as #WCLC20. #LCSM
#LCSM Chat @lcsmchat
RT @HenningWillers: @BrendonStilesMD hmmpf, as usual no #radonc advances (we need to do better) #lcsm
Dave Bjork @bjork5
@BrendonStilesMD You rock this Brendon! #LCSM
Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh
#lcsm hello everyone Kim here from Canada
Brendon Stiles @BrendonStilesMD
T1. Can and should we screen for lung cancer in never smokers? #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience #lcsm
Stacey Tinianov @coffeemommy
@JFreemanDaily If you're using https://t.co/e5rnQ1Ff9H it's acting a bit wonky tonight. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to fol…
Brendon Stiles @BrendonStilesMD
T1. This has long been a data free zone. #lcsm
Brendon Stiles @BrendonStilesMD
T1. Although I understand the desire for this in the #lcsm community, challenge to justify expected costs, low + rates, and potential complications. #lcsm
Dave Bjork @bjork5
Woohoo! @NarjustDumaMD 🙌 #LCSM
#LCSM Chat @lcsmchat
@n8pennell Hello famous @people correspondent. #lcsm
Brendon Stiles @BrendonStilesMD
T1. In general, I have always argued that we need to show that we can be successful in approved populations before expanding more broadly. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. Can and should we screen for lung cancer in never smokers? #lcsm
#LCSM Chat @lcsmchat
@CroixDenise Welcome! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. This has long been a data free zone. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. Although I understand the desire for this in the #lcsm community, challenge to justify expected costs, low + rate…
#LCSM Chat @lcsmchat
@MimiProvenzano Hi Mimi #lcsm
mimiprovenzano @MimiProvenzano
RT @BrendonStilesMD: T1. Can and should we screen for lung cancer in never smokers? #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: #LungCancer led the way with newsworthy presentations. Great summary here from @StephenVLiu @NarjustDumaMD and Ross S…
Stephen V Liu @StephenVLiu
RT @BrendonStilesMD: T1. Can and should we screen for lung cancer in never smokers? #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @HenningWillers @BrendonStilesMD We can't cover everything in one hour! I believe some #radonc advances were presented…
Brendon Stiles @BrendonStilesMD
T1. However, some glimmers of hope at #WCLC20, particularly TALENT trial. #lcsm https://t.co/zQpTRcOXXA
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. In general, I have always argued that we need to show that we can be successful in approved populations before ex…
#LCSM Chat @lcsmchat
@Kamacintosh Hi Kim #lcsm
mimiprovenzano @MimiProvenzano
@lcsmchat Hey Deanna! #lcsm
Jill Feldman @jillfeldman4
T1 This is a tough one. LDCT are not ideal for screening because something is found on majority of people & around 90% of the time it's not cancer. Not easy to tell someone (who knows nothing about #lungcancer) that a small nodule was found but wait 6 mths to scan #LCSM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. Can and should we screen for lung cancer in never smokers? #lcsm
#LCSM Chat @lcsmchat
RT @coffeemommy: @JFreemanDaily If you're using https://t.co/e5rnQ1Ff9H it's acting a bit wonky tonight. #lcsm
Inspire @teaminspire
RT @BrendonStilesMD: T1. However, some glimmers of hope at #WCLC20, particularly TALENT trial. #lcsm https://t.co/zQpTRcOXXA
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. This has long been a data free zone. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. Although I understand the desire for this in the #lcsm community, challenge to justify expected costs, low + rate…
Brendon Stiles @BrendonStilesMD
T1. In TALENT, they screened light or never smokers in Taiwan. #lcsm https://t.co/xyDHmv0UXI
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: #LungCancer led the way with newsworthy presentations. Great summary here from @StephenVLiu @NarjustDumaMD and Ross S…
Stacey Tinianov @coffeemommy
@BrendonStilesMD Since never smoker lung cancer is on the rise, methinks it is definitely time to look at including other risk factors in the screening criteria. Family history is a big one. But also we seem to be seeing a helluva lot of potentially pollution-induced cancers. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. In general, I have always argued that we need to show that we can be successful in approved populations before ex…
kristen kimball @KimballKristen
@JFreemanDaily It does seem more difficult tonight! #LCSM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. However, some glimmers of hope at #WCLC20, particularly TALENT trial. #lcsm https://t.co/zQpTRcOXXA
#LCSM Chat @lcsmchat
RT @jillfeldman4: T1 This is a tough one. LDCT are not ideal for screening because something is found on majority of people & around 90% of…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. In TALENT, they screened light or never smokers in Taiwan. #lcsm https://t.co/xyDHmv0UXI
#LCSM Chat @lcsmchat
RT @coffeemommy: @BrendonStilesMD Since never smoker lung cancer is on the rise, methinks it is definitely time to look at including other…
Inspire @teaminspire
Hello to the #lcsm community, John Novack grateful here on behalf of Inspire, to listen and learn.
Brendon Stiles @BrendonStilesMD
T1. Remarkably, they found lung cancer in 2.1% of patients, including over 95% with early stage (0/I) cancer. #lcsm https://t.co/xVcsLLWGHn
Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh
RT @BrendonStilesMD: T1. In TALENT, they screened light or never smokers in Taiwan. #lcsm https://t.co/xyDHmv0UXI
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. However, some glimmers of hope at #WCLC20, particularly TALENT trial. #lcsm https://t.co/zQpTRcOXXA
Janet Freeman-Daily @JFreemanDaily
RT @jillfeldman4: T1 This is a tough one. LDCT are not ideal for screening because something is found on majority of people & around 90% of…
Lillian Leigh @ProjectBreath
T1. Thank goodness this is no longer the case! Results from the TALENT study from Taiwan, as reported at @WCLC20, is a fantastic start to us having data to justify screening in never smokers. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. In TALENT, they screened light or never smokers in Taiwan. #lcsm https://t.co/xyDHmv0UXI
Kimberley H Geissler @khgeissler
@BrendonStilesMD T1. Is there any evidence of higher risk in eg, never smoker daughter of never smoker with LC? #lcsm
Stephen V Liu @StephenVLiu
@BrendonStilesMD T1: there’s definitely a need. You’re referring to the TALENT trial that used CT screening in non-smokers in Taiwan. But it will be hard to show a similar impact in a region with a lower incidence. Balance benefit with cost and risks. #LCSM
Brendon Stiles @BrendonStilesMD
T1. This detection rate is HIGHER than that in large trials of smokers! #lcsm https://t.co/TJF01Ul6b0
Janet Freeman-Daily @JFreemanDaily
RT @coffeemommy: @BrendonStilesMD Since never smoker lung cancer is on the rise, methinks it is definitely time to look at including other…
Brendon Stiles @BrendonStilesMD
RT @ProjectBreath: T1. Thank goodness this is no longer the case! Results from the TALENT study from Taiwan, as reported at @WCLC20, is a f…
Deepti Behl, M.D. @deeptibehl1
@JFreemanDaily Yes me too, feel like not seeing it all #lcsm
Nathan A. Pennell MD, PhD, FASCO @n8pennell
T1. The Taiwan screening study (2.6% I think incidence in nonsmokers) suggests at least there screening makes great sense. Unclear how much that translates outside Asia. #lcsm
Jamie Holloway, PhD @jamienholloway
Jumping in late to the #LCSM chat, eager to hear more from world lung!
Christine Qiong Wu @wi_qiong
@BrendonStilesMD Yes, >10% of us are never smokers. #LCSM
Jill Feldman @jillfeldman4
T1 BUT there are many factors in addition to smoking history that we know like family history, outdoor air pollution, radon, etc. It's ridiculous that current guidelines only include smoking history and age - it's an incomplete way & misses a lot of people #LCSM
Brendon Stiles @BrendonStilesMD
T1. The most important slide to me was the one that showed association with family history. Clearly should consider that as a criteria for screening. #lcsm https://t.co/cOkcpwmeUU
#LCSM Chat @lcsmchat
@deeptibehl1 @EricBernicker Welcome! Remember to include #lcsm in your tweets so we can see them during the chat.
Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh
@ProjectBreath Totally agree #lcsm
mimiprovenzano @MimiProvenzano
RT @BrendonStilesMD: T1. Remarkably, they found lung cancer in 2.1% of patients, including over 95% with early stage (0/I) cancer. #lcsm h…
Sue McCullough @SueMcCu30398663
#LCSM I think I will just watch the tweets for a while, I much rather talking, I just don't type fast.
Flemming Rasmussen @fgrazz
@LungCancerFaces @lcsmchat and @fgrazz from Halifax listening in #lcsm
Stacey Tinianov @coffeemommy
@BrendonStilesMD @JFreemanDaily If you're just now getting "sick" of it, you are far more robust than I am. Thinking I started to crack from hug withdrawl about 3 weeks in last Spring. Looking forward to post-vaccine hugging before the end of the year. #lcsm
mimiprovenzano @MimiProvenzano
RT @BrendonStilesMD: T1. This detection rate is HIGHER than that in large trials of smokers! #lcsm https://t.co/TJF01Ul6b0
Nathan A. Pennell MD, PhD, FASCO @n8pennell
RT @BrendonStilesMD: T1. Remarkably, they found lung cancer in 2.1% of patients, including over 95% with early stage (0/I) cancer. #lcsm h…
#LCSM Chat @lcsmchat
@teaminspire Hi John #lcsm
Brendon Stiles @BrendonStilesMD
T1. There was also a great poster on genetic risk and ground glass nodules (1512) that I discussed here - https://t.co/x9hPPhI5pa Is there likely an inheritable risk of lung cancer... #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. Remarkably, they found lung cancer in 2.1% of patients, including over 95% with early stage (0/I) cancer. #lcsm h…
Lillian Leigh @ProjectBreath
@jillfeldman4 That's a really good point @jillfeldman4. Do you think that this challenge would reduce over time when there's more understanding in the general public about #lungcancer as well as other lung disease? #lcsm
#LCSM Chat @lcsmchat
RT @ProjectBreath: T1. Thank goodness this is no longer the case! Results from the TALENT study from Taiwan, as reported at @WCLC20, is a f…
#LCSM Chat @lcsmchat
RT @khgeissler: @BrendonStilesMD T1. Is there any evidence of higher risk in eg, never smoker daughter of never smoker with LC? #lcsm
#LCSM Chat @lcsmchat
RT @StephenVLiu: @BrendonStilesMD T1: there’s definitely a need. You’re referring to the TALENT trial that used CT screening in non-smokers…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. This detection rate is HIGHER than that in large trials of smokers! #lcsm https://t.co/TJF01Ul6b0
#LCSM Chat @lcsmchat
RT @n8pennell: T1. The Taiwan screening study (2.6% I think incidence in nonsmokers) suggests at least there screening makes great sense. U…
#LCSM Chat @lcsmchat
@jamienholloway Thanks for joining! #lcsm
Janet Freeman-Daily @JFreemanDaily
@coffeemommy @BrendonStilesMD The challenge (always) is showing evidence that persons with any given risk factor will benefit enough from #lungcancer screening to justify the risks. Can only due that through a clinical trial. #LCSM
Brendon Stiles @BrendonStilesMD
@coffeemommy @JFreemanDaily I am going to hug the heck out of many people. It is going to be uncomfortable. Apologizing in advance. #lcsm
Stephen V Liu @StephenVLiu
@BrendonStilesMD T1: we also saw very interesting data about germline mutations in #SCLC - hereditary risk may be more prevalent than we previously thought. #LCSM
#LCSM Chat @lcsmchat
RT @jillfeldman4: T1 BUT there are many factors in addition to smoking history that we know like family history, outdoor air pollution, rad…
Nathan A. Pennell MD, PhD, FASCO @n8pennell
RT @BrendonStilesMD: T1. The most important slide to me was the one that showed association with family history. Clearly should consider…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. The most important slide to me was the one that showed association with family history. Clearly should consider…
KRASKickers @kRasKickers
@JFreemanDaily #LCSM chat Hey all - I am fashionably late this evening ./ This is Terri
mimiprovenzano @MimiProvenzano
RT @BrendonStilesMD: T1. The most important slide to me was the one that showed association with family history. Clearly should consider…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. Remarkably, they found lung cancer in 2.1% of patients, including over 95% with early stage (0/I) cancer. #lcsm h…
Nicole Rossi MD Oncologist @NicoleRossiOnco
RT @BrendonStilesMD: I am tired of virtual meetings. I need to see, talk to, hug, laugh with friends, colleagues, and new acquaintances.…
Nicole Rossi MD Oncologist @NicoleRossiOnco
Me too
Janet Freeman-Daily @JFreemanDaily
RT @ProjectBreath: T1. Thank goodness this is no longer the case! Results from the TALENT study from Taiwan, as reported at @WCLC20, is a f…
#LCSM Chat @lcsmchat
@SueMcCu30398663 We were all newbies once. You’ll get the hang of it. I promise. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @StephenVLiu: @BrendonStilesMD T1: there’s definitely a need. You’re referring to the TALENT trial that used CT screening in non-smokers…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. This detection rate is HIGHER than that in large trials of smokers! #lcsm https://t.co/TJF01Ul6b0
Brendon Stiles @BrendonStilesMD
@StephenVLiu Totally agree. But it starts us on a dialogue for identifying risk - genetic, ethnic, environmental. We'll get there eventually. #lcsm
Lillian Leigh @ProjectBreath
RT @StephenVLiu: @BrendonStilesMD T1: we also saw very interesting data about germline mutations in #SCLC - hereditary risk may be more pre…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. There was also a great poster on genetic risk and ground glass nodules (1512) that I discussed here - https://t.c…
Janet Freeman-Daily @JFreemanDaily
RT @n8pennell: T1. The Taiwan screening study (2.6% I think incidence in nonsmokers) suggests at least there screening makes great sense. U…
#LCSM Chat @lcsmchat
RT @ProjectBreath: @jillfeldman4 That's a really good point @jillfeldman4. Do you think that this challenge would reduce over time when the…
Jill Feldman @jillfeldman4
@ProjectBreath Educating people is key. I feel like once it's explained in a way that people can understand it's less anxiety provoking, but there are still those who won't be able to compartmentalize and there is no easy way to do a lung biopsy! #LCSM
Eric Bernicker @EricBernicker
@jillfeldman4 Completely agree but until we prove that we can screen folks with a certain smoking history--and the numbers are awful--expanding to other populations will be difficult #LCSM
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @coffeemommy @BrendonStilesMD The challenge (always) is showing evidence that persons with any given risk factor will be…
#LCSM Chat @lcsmchat
RT @StephenVLiu: @BrendonStilesMD T1: we also saw very interesting data about germline mutations in #SCLC - hereditary risk may be more pre…
Stephen V Liu @StephenVLiu
RT @BrendonStilesMD: #LungCancer led the way with newsworthy presentations. Great summary here from @StephenVLiu @NarjustDumaMD and Ross S…
Janet Freeman-Daily @JFreemanDaily
RT @jillfeldman4: T1 BUT there are many factors in addition to smoking history that we know like family history, outdoor air pollution, rad…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. The most important slide to me was the one that showed association with family history. Clearly should consider…
Brendon Stiles @BrendonStilesMD
Another of my all time favorites! Love seeing your here! #lcsm
#LCSM Chat @lcsmchat
@kRasKickers @JFreemanDaily Hey Terri! #lcsm
Jill Feldman @jillfeldman4
RT @StephenVLiu: @BrendonStilesMD T1: we also saw very interesting data about germline mutations in #SCLC - hereditary risk may be more pre…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @StephenVLiu Totally agree. But it starts us on a dialogue for identifying risk - genetic, ethnic, environmental. We…
#LCSM Chat @lcsmchat
RT @jillfeldman4: @ProjectBreath Educating people is key. I feel like once it's explained in a way that people can understand it's less anx…
Jill Feldman @jillfeldman4
RT @BrendonStilesMD: T1. There was also a great poster on genetic risk and ground glass nodules (1512) that I discussed here - https://t.c…
Stacey Tinianov @coffeemommy
@jillfeldman4 Indeed the idea of watchful waiting is hard. Hoping that there will be other ways to intelligently screen high risk populations (across all cancers) moving forward. Liquid biopsies as screening aren't there yet but have potential. #lcsm
#LCSM Chat @lcsmchat
RT @EricBernicker: @jillfeldman4 Completely agree but until we prove that we can screen folks with a certain smoking history--and the numbe…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. There was also a great poster on genetic risk and ground glass nodules (1512) that I discussed here - https://t.c…
Chief Judith Roney-Carroll(Ret.)REDSTORMRISE^2022 @cbpd800
RT @JFreemanDaily: @coffeemommy @BrendonStilesMD The challenge (always) is showing evidence that persons with any given risk factor will be…
#LCSM Chat @lcsmchat
RT @coffeemommy: @jillfeldman4 Indeed the idea of watchful waiting is hard. Hoping that there will be other ways to intelligently screen hi…
Janet Freeman-Daily @JFreemanDaily
RT @ProjectBreath: @jillfeldman4 That's a really good point @jillfeldman4. Do you think that this challenge would reduce over time when the…
Eric Bernicker @EricBernicker
@BrendonStilesMD @StephenVLiu I am hopeful that the increasing recognition on the need for environmental justice and pollution will lead to this being explored more thoroughly #LCSM
Ronald Clarke @RonaldClarke
RT @StephenVLiu: #ASCO20 Potential role of AXL in mediating acquired TKI resistance across fusion positive NSCLC (#ALK, #ROS1, #RET) and ad…
Stephen V Liu @StephenVLiu
@BrendonStilesMD T1: And CT is not our only screening tool. I’m very optimistic that we will be using blood-based screening strategies in the not too distant future. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @JFreemanDaily: @coffeemommy @BrendonStilesMD The challenge (always) is showing evidence that persons with any given risk factor will be…
Dr Riyaz Shah @DrRiyazShah
T1, ultimitly at population level, LDCT wil be an issue. Need non invasive/radiation exposure based screening tests. Not sure what will win, blood, urine breath? something will. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @StephenVLiu: @BrendonStilesMD T1: we also saw very interesting data about germline mutations in #SCLC - hereditary risk may be more pre…
Inspire @teaminspire
RT @JFreemanDaily: @coffeemommy @BrendonStilesMD The challenge (always) is showing evidence that persons with any given risk factor will be…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: @StephenVLiu Totally agree. But it starts us on a dialogue for identifying risk - genetic, ethnic, environmental. We…
Brendon Stiles @BrendonStilesMD
T2 coming soon. Long way to go on screening never smokers, but research and trials will get us there. In the interim, let's increase screening rates in eligible patients! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @jillfeldman4: @ProjectBreath Educating people is key. I feel like once it's explained in a way that people can understand it's less anx…
#LCSM Chat @lcsmchat
I see you @SeastedtMD! Thanks for joining us. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @EricBernicker: @jillfeldman4 Completely agree but until we prove that we can screen folks with a certain smoking history--and the numbe…
kristen kimball @KimballKristen
T1 eagerly awaiting the day my adult kids qualify for screening...we don’t know why husband Dave/their dad got + died of EGFR+ LC. Hoping for biomarker or other breakthroughs for them & all ppl #lcsm
Jill Feldman @jillfeldman4
@coffeemommy The Holy Grail of early detection! #LCSM
Laura Greco @lgreco_ny
@StephenVLiu @BrendonStilesMD T1: I think this will be a game changer. #LCSM
Inspire @teaminspire
RT @BrendonStilesMD: T1. The most important slide to me was the one that showed association with family history. Clearly should consider…
Charu Aggarwal, MD, MPH @CharuAggarwalMD
Definitely something to look forward to in the future #LCSM
#LCSM Chat @lcsmchat
RT @EricBernicker: @BrendonStilesMD @StephenVLiu I am hopeful that the increasing recognition on the need for environmental justice and pol…
Brendon Stiles @BrendonStilesMD
T2. How will KRAS inhibitors fit into the treatment of lung cancer? My oncology friends better answer! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @coffeemommy: @jillfeldman4 Indeed the idea of watchful waiting is hard. Hoping that there will be other ways to intelligently screen hi…
#LCSM Chat @lcsmchat
RT @StephenVLiu: @BrendonStilesMD T1: And CT is not our only screening tool. I’m very optimistic that we will be using blood-based screenin…
#LCSM Chat @lcsmchat
RT @DrRiyazShah: T1, ultimitly at population level, LDCT wil be an issue. Need non invasive/radiation exposure based screening tests. Not s…
Brendon Stiles @BrendonStilesMD
@MattSmeltzer Dramatically is my guess! #lcsm
Gabriela Candás @gbc02
RT @BrendonStilesMD: I am tired of virtual meetings. I need to see, talk to, hug, laugh with friends, colleagues, and new acquaintances.…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2 coming soon. Long way to go on screening never smokers, but research and trials will get us there. In the interim…
#LCSM Chat @lcsmchat
RT @KimballKristen: T1 eagerly awaiting the day my adult kids qualify for screening...we don’t know why husband Dave/their dad got + died o…
Janet Freeman-Daily @JFreemanDaily
RT @StephenVLiu: @BrendonStilesMD T1: And CT is not our only screening tool. I’m very optimistic that we will be using blood-based screenin…
kristen kimball @KimballKristen
@StephenVLiu @BrendonStilesMD Yes, hopping for this! #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @DrRiyazShah: T1, ultimitly at population level, LDCT wil be an issue. Need non invasive/radiation exposure based screening tests. Not s…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2 coming soon. Long way to go on screening never smokers, but research and trials will get us there. In the interim…
Janet Freeman-Daily @JFreemanDaily
RT @KimballKristen: T1 eagerly awaiting the day my adult kids qualify for screening...we don’t know why husband Dave/their dad got + died o…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. How will KRAS inhibitors fit into the treatment of lung cancer? My oncology friends better answer! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @jillfeldman4: @coffeemommy The Holy Grail of early detection! #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: Definitely something to look forward to in the future #LCSM https://t.co/yaWjiktlZs
#LCSM Chat @lcsmchat
#lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. How will KRAS inhibitors fit into the treatment of lung cancer? My oncology friends better answer! #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@BrendonStilesMD I am personally looking forward to offering it to my patients in the 2L setting. Another reason to #Test #LCSM
Brendon Stiles @BrendonStilesMD
T2. Tough target, long time coming. #lcsm
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: @BrendonStilesMD I am personally looking forward to offering it to my patients in the 2L setting. Another reason to #T
Stephen V Liu @StephenVLiu
@BrendonStilesMD T2: as soon as they are available, they will instantly become the preferred standard second line treatment. Use in the first line will need to be combinations unless we can further in which the population that get long-term benefit. #LCSM
Jill Feldman @jillfeldman4
@DrRiyazShah We need a universal, cost effective, non invasive, with high sensitivity/specificity screening tool - not too much to ask for :) #LCSM
KRASKickers @kRasKickers
RT @JFreemanDaily: @watchyourcharts @BrendonStilesMD Welcome to #LCSM Chat! Our chats are structured around specific questions. You can r…
Stacey Tinianov @coffeemommy
@jillfeldman4 I simply cannot see/hear/read that phrase without busting into some quotable Monty Python quotes "It's just a flesh wound..." #lcsm
Lori BURWELL @lori_burwell
RT @lgreco_ny: Please share like your life depends on it. LIVES DO DEPEND ON IT. Churchill: Why won't New York vaccinate the vulnerable? #l
Charu Aggarwal, MD, MPH @CharuAggarwalMD
Reinforces the need for comprehensive molecular testing #NGS #LCSM
Eric Bernicker @EricBernicker
@BrendonStilesMD Not exactly the Wonka golden ticket yet but man we have been waiting for active drugs in this space for such a long time. Very exciting #LCSM
Brendon Stiles @BrendonStilesMD
T2. The update on the CodeBreaK 100 trial with Sotorasib for KRAS pG12C mutated NSCLC was presented. #lcsm https://t.co/Qw2G4o4Dli
#LCSM Chat @lcsmchat
I see you @CCuadra8! Thanks for joining us. #lcsm
Brendon Stiles @BrendonStilesMD
RT @StephenVLiu: @BrendonStilesMD T2: as soon as they are available, they will instantly become the preferred standard second line treatmen…
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: @BrendonStilesMD I am personally looking forward to offering it to my patients in the 2L setting. Another reason to #T
Nathan A. Pennell MD, PhD, FASCO @n8pennell
T2. KRAS G12C inhibitors likely to immediately move into second/third line behind PD1 and/or chemo-IO. Probably not first line yet. But promising first step that will lead to better treatments soon #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Tough target, long time coming. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Tough target, long time coming. #lcsm
#LCSM Chat @lcsmchat
RT @StephenVLiu: @BrendonStilesMD T2: as soon as they are available, they will instantly become the preferred standard second line treatmen…
Janet Freeman-Daily @JFreemanDaily
RT @StephenVLiu: @BrendonStilesMD T2: as soon as they are available, they will instantly become the preferred standard second line treatmen…
Brendon Stiles @BrendonStilesMD
T2. And here are the results: #lcsm https://t.co/7zZWgEK5lz
#LCSM Chat @lcsmchat
RT @jillfeldman4: @DrRiyazShah We need a universal, cost effective, non invasive, with high sensitivity/specificity screening tool - not to…
Janet Freeman-Daily @JFreemanDaily
RT @jillfeldman4: @DrRiyazShah We need a universal, cost effective, non invasive, with high sensitivity/specificity screening tool - not to…
Dr Riyaz Shah @DrRiyazShah
T2: Compassionate use programme for Sotorasib opened in the UK yesterday. Only for those not elibible for trials. We are moving to a national ngs based genomic model that will detect large numbers of these patients. For now its not a 1st line drug #LCSM
Henning Willers, MD @HenningWillers
RT @BrendonStilesMD: T2. The update on the CodeBreaK 100 trial with Sotorasib for KRAS pG12C mutated NSCLC was presented. #lcsm https://t.…
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: Reinforces the need for comprehensive molecular testing #NGS #LCSM
Hossen Mahmud, MD @DrHMahmudMD
RT @BrendonStilesMD: I am tired of virtual meetings. I need to see, talk to, hug, laugh with friends, colleagues, and new acquaintances.…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. The update on the CodeBreaK 100 trial with Sotorasib for KRAS pG12C mutated NSCLC was presented. #lcsm https://t.…
Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh
RT @jillfeldman4: @DrRiyazShah We need a universal, cost effective, non invasive, with high sensitivity/specificity screening tool - not to…
#LCSM Chat @lcsmchat
RT @EricBernicker: @BrendonStilesMD Not exactly the Wonka golden ticket yet but man we have been waiting for active drugs in this space for…
Brendon Stiles @BrendonStilesMD
@EricBernicker I am so on the look out for a Wonka ticket! #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
We must remember that Immunotherapy alone, and in combination with chemotherapy has great efficacy in 1L setting, so till we see data in the 1L setting, we should use these in 2L #LCSM
#LCSM Chat @lcsmchat
RT @n8pennell: T2. KRAS G12C inhibitors likely to immediately move into second/third line behind PD1 and/or chemo-IO. Probably not first li…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. And here are the results: #lcsm https://t.co/7zZWgEK5lz
#LCSM Chat @lcsmchat
RT @DrRiyazShah: T2: Compassionate use programme for Sotorasib opened in the UK yesterday. Only for those not elibible for trials. We are m…
Stephen V Liu @StephenVLiu
@BrendonStilesMD T2: this subset of cancers can also respond quite well to immunotherapy and those responses can be exceptionally durable. I’m not willing to trade that for the targeted agents just yet. So the first line setting for me is still immunotherapy-based. #LCSM
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: We must remember that Immunotherapy alone, and in combination with chemotherapy has great efficacy in 1L setting, so t…
Brendon Stiles @BrendonStilesMD
T2. Nice summary from @HemOncToday #lcsm https://t.co/YtxChvAPat
#LCSM Chat @lcsmchat
RT @StephenVLiu: @BrendonStilesMD T2: this subset of cancers can also respond quite well to immunotherapy and those responses can be except…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Nice summary from @HemOncToday #lcsm https://t.co/YtxChvAPat
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@DrRiyazShah What is the national NGS model? #LCSM
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: @DrRiyazShah What is the national NGS model? #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. The update on the CodeBreaK 100 trial with Sotorasib for KRAS pG12C mutated NSCLC was presented. #lcsm https://t.…
Brendon Stiles @BrendonStilesMD
T2. Great thread from @Jbauml about the trial. #lcsm https://t.co/oWOjlppjih
Janet Freeman-Daily @JFreemanDaily
RT @EricBernicker: @BrendonStilesMD Not exactly the Wonka golden ticket yet but man we have been waiting for active drugs in this space for…
Stacey Tinianov @coffeemommy
@BrendonStilesMD Well, with one more tool in the toolbox, hopefully before we even get to treatment we will get to biomarker testing as a STANDARD at diagnosis. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @n8pennell: T2. KRAS G12C inhibitors likely to immediately move into second/third line behind PD1 and/or chemo-IO. Probably not first li…
kristen kimball @KimballKristen
@StephenVLiu @BrendonStilesMD Hoping now, will be hopping w joy when it happens #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. And here are the results: #lcsm https://t.co/7zZWgEK5lz
Brendon Stiles @BrendonStilesMD
T2. Very good response in these pretreated patients. Questions remain about duration of response. #lcsm From @herbloong https://t.co/lENIV32HJ0
#LCSM Chat @lcsmchat
I see you @ErikaHlavacek! Thanks for joining. #lcsm
Henning Willers, MD @HenningWillers
RT @BrendonStilesMD: T2. Nice summary from @HemOncToday #lcsm https://t.co/YtxChvAPat
Lillian Leigh @ProjectBreath
T2. Amazing to see this waterfall plot - a long time coming, and definitely a game-changer given that the rate of KRAS is so high in lung adenocarcinoma! #LCSM https://t.co/TgN14FSzrY
Janet Freeman-Daily @JFreemanDaily
@BrendonStilesMD Lookit that lovely KRAS targeted therapy waterfall plot! Hopeful. #LCSM
kristen kimball @KimballKristen
@lgreco_ny @StephenVLiu @BrendonStilesMD T1 yes or will #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @DrRiyazShah: T2: Compassionate use programme for Sotorasib opened in the UK yesterday. Only for those not elibible for trials. We are m…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Tim here. Happy to be able to join the #lcsm discussion. #PatientsFirst
Brendon Stiles @BrendonStilesMD
T2. Important to remember that these are pretreated patients. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: We must remember that Immunotherapy alone, and in combination with chemotherapy has great efficacy in 1L setting, so t…
Brendon Stiles @BrendonStilesMD
@TimAllenMDJD Hi Tim! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @StephenVLiu: @BrendonStilesMD T2: this subset of cancers can also respond quite well to immunotherapy and those responses can be except…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @ProjectBreath: T2. Amazing to see this waterfall plot - a long time coming, and definitely a game-changer given that the rate of KRAS i…
Sue McCullough @SueMcCu30398663
I have at least updated my profile. #LCSM
Henning Willers, MD @HenningWillers
@BrendonStilesMD @HemOncToday Unfortunately the response rates really come down. Combination drug therapies will be needed #lcsm
#LCSM Chat @lcsmchat
@jillfeldman4 @CCuadra8 If someone “likes” a tweet, I can see it. #lcsm
Karma Macgregor @KarmaMacgregor
RT @JillHW: Terrific news! On behalf of Canadians affected by lung cancer, thank you. #lcsm
KRASKickers @kRasKickers
RT @CharuAggarwalMD: @BrendonStilesMD I am personally looking forward to offering it to my patients in the 2L setting. Another reason to #T
Dr Riyaz Shah @DrRiyazShah
@CharuAggarwalMD all patients with cancer across the country get NGS targeted at their tumour. There is a "national test directory" for each tumour site. In theory a comprehensive programme to deliver NGS across the nation to all eligible pts. Ambitious and still nascent but happening. #LCSM
#LCSM Chat @lcsmchat
Hi @JohnLPender! Hope you’re doing OK. #LCSM
Brendon Stiles @BrendonStilesMD
@HenningWillers @HemOncToday T2. Lots of combinations coming. #lcsm Slide from @molina_arcas https://t.co/lk6QYQgdNj
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Nice summary from @HemOncToday #lcsm https://t.co/YtxChvAPat
Daniel Nava Rodrigues @daninava
RT @n8pennell: T2. KRAS G12C inhibitors likely to immediately move into second/third line behind PD1 and/or chemo-IO. Probably not first li…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Great thread from @Jbauml about the trial. #lcsm https://t.co/oWOjlppjih
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Howdy, @BrendonStilesMD! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @coffeemommy: @BrendonStilesMD Well, with one more tool in the toolbox, hopefully before we even get to treatment we will get to biomark…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @DrRiyazShah: @CharuAggarwalMD all patients with cancer across the country get NGS targeted at their tumour. There is a "national test d…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Great thread from @Jbauml about the trial. #lcsm https://t.co/oWOjlppjih
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Very good response in these pretreated patients. Questions remain about duration of response. #lcsm From @herbl
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@HenningWillers @BrendonStilesMD @HemOncToday I wouldn't say that RR are "down". These are complex microenvironments, quite distinct from EGFR/ALK/ROS. I think 37% is pretty exciting! #LCSM
#LCSM Chat @lcsmchat
RT @coffeemommy: @BrendonStilesMD Well, with one more tool in the toolbox, hopefully before we even get to treatment we will get to biomark…
Brendon Stiles @BrendonStilesMD
T3 coming soon! #lcsm
Nathan A. Pennell MD, PhD, FASCO @n8pennell
RT @BrendonStilesMD: @HenningWillers @HemOncToday T2. Lots of combinations coming. #lcsm Slide from @molina_arcas https://t.co/lk6QYQgdNj
Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh
RT @coffeemommy: @BrendonStilesMD Well, with one more tool in the toolbox, hopefully before we even get to treatment we will get to biomark…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Very good response in these pretreated patients. Questions remain about duration of response. #lcsm From @herbl
#LCSM Chat @lcsmchat
RT @ProjectBreath: T2. Amazing to see this waterfall plot - a long time coming, and definitely a game-changer given that the rate of KRAS i…
Janet Freeman-Daily @JFreemanDaily
RT @ProjectBreath: T2. Amazing to see this waterfall plot - a long time coming, and definitely a game-changer given that the rate of KRAS i…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
#hope #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @BrendonStilesMD Lookit that lovely KRAS targeted therapy waterfall plot! Hopeful. #LCSM
Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh
@coffeemommy @JFreemanDaily @BrendonStilesMD Agree #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Important to remember that these are pretreated patients. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Important to remember that these are pretreated patients. #lcsm
#LCSM Chat @lcsmchat
@SueMcCu30398663 Love the pic! #lcsm
Brendon Stiles @BrendonStilesMD
T3. What is new in mesothelioma and small cell lung cancer? #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @HenningWillers: @BrendonStilesMD @HemOncToday Unfortunately the response rates really come down. Combination drug therapies will be nee…
Lillian Leigh @ProjectBreath
@CharuAggarwalMD @HenningWillers @BrendonStilesMD @HemOncToday Can you please expand on this @CharuAggarwalMD? I'm interested to hear more #lcsm
#LCSM Chat @lcsmchat
RT @HenningWillers: @BrendonStilesMD @HemOncToday Unfortunately the response rates really come down. Combination drug therapies will be nee…
#LCSM Chat @lcsmchat
RT @DrRiyazShah: @CharuAggarwalMD all patients with cancer across the country get NGS targeted at their tumour. There is a "national test d…
Lillian Leigh @ProjectBreath
RT @BrendonStilesMD: @HenningWillers @HemOncToday T2. Lots of combinations coming. #lcsm Slide from @molina_arcas https://t.co/lk6QYQgdNj
Brendon Stiles @BrendonStilesMD
RT @ProjectBreath: @CharuAggarwalMD @HenningWillers @BrendonStilesMD @HemOncToday Can you please expand on this @CharuAggarwalMD? I'm inter…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
2d that! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @HenningWillers @HemOncToday T2. Lots of combinations coming. #lcsm Slide from @molina_arcas https://t.co/lk6QYQgdNj
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: @HenningWillers @BrendonStilesMD @HemOncToday I wouldn't say that RR are "down". These are complex microenvironments,…
Janet Freeman-Daily @JFreemanDaily
RT @DrRiyazShah: @CharuAggarwalMD all patients with cancer across the country get NGS targeted at their tumour. There is a "national test d…
Jill Feldman @jillfeldman4
T2 It's a huge step for #KRAS and 13% have G12C so big unmet need. That's important for a population that was considered un-targetable. #LCSM
Deepti Behl, M.D. @deeptibehl1
@DrRiyazShah Blood 🩸 based testing showing promise #lcsm
Eric Bernicker @EricBernicker
@JFreemanDaily @BrendonStilesMD I'm not crying, you're.......ok I AM crying. The potential numbers of patients who could potentially benefit is immense. Many years of effort and study and prayer on that waterfall plot... #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: @HenningWillers @HemOncToday T2. Lots of combinations coming. #lcsm Slide from @molina_arcas https://t.co/lk6QYQgdNj
KRASKickers @kRasKickers
RT @BrendonStilesMD: T2. How will KRAS inhibitors fit into the treatment of lung cancer? My oncology friends better answer! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: @HenningWillers @BrendonStilesMD @HemOncToday I wouldn't say that RR are "down". These are complex microenvironments,…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. What is new in mesothelioma and small cell lung cancer? #lcsm
#LCSM Chat @lcsmchat
RT @ProjectBreath: @CharuAggarwalMD @HenningWillers @BrendonStilesMD @HemOncToday Can you please expand on this @CharuAggarwalMD? I'm inter…
Brendon Stiles @BrendonStilesMD
T3. Mesothelioma and small cell are too often left behind. Both terrible diseases. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. What is new in mesothelioma and small cell lung cancer? #lcsm
#LCSM Chat @lcsmchat
RT @jillfeldman4: T2 It's a huge step for #KRAS and 13% have G12C so big unmet need. That's important for a population that was considered…
Erika Hlavacek @ErikaHlavacek
so true with unmet need!
Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh
@jillfeldman4 A game changer #LCSM
#LCSM Chat @lcsmchat
RT @EricBernicker: @JFreemanDaily @BrendonStilesMD I'm not crying, you're.......ok I AM crying. The potential numbers of patients who could…
Brendon Stiles @BrendonStilesMD
T3. The CONFIRM trial assessed Nivolumab in relapsed mesothelioma. #lcsm From @DrRiyazShah https://t.co/ZqNPtLVmNv
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @jillfeldman4: T2 It's a huge step for #KRAS and 13% have G12C so big unmet need. That's important for a population that was considered…
#LCSM Chat @lcsmchat
RT @deeptibehl1: @DrRiyazShah Blood 🩸 based testing showing promise #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @EricBernicker: @JFreemanDaily @BrendonStilesMD I'm not crying, you're.......ok I AM crying. The potential numbers of patients who could…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Mesothelioma and small cell are too often left behind. Both terrible diseases. #lcsm
Henning Willers, MD @HenningWillers
@BrendonStilesMD @HemOncToday @molina_arcas Naturally we are working on combining KRAS G12C inhibition with #radiotherapy #radonc #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. The CONFIRM trial assessed Nivolumab in relapsed mesothelioma. #lcsm From @DrRiyazShah https://t.co/ZqNPtLVmNv
#LCSM Chat @lcsmchat
RT @HenningWillers: @BrendonStilesMD @HemOncToday @molina_arcas Naturally we are working on combining KRAS G12C inhibition with #radiothera
Sue McCullough @SueMcCu30398663
#LCSM Lillian,I think next time I need you socially distant showing me how to 'be apart of the discussions.'
Janet Freeman-Daily @JFreemanDaily
RT @EricBernicker: @JFreemanDaily @BrendonStilesMD I'm not crying, you're.......ok I AM crying. The potential numbers of patients who could…
Brendon Stiles @BrendonStilesMD
@HenningWillers @HemOncToday @molina_arcas #lcsm https://t.co/KflK3kTovA
Mighty #HardToKill Casey she/her ☀️ @MightyCasey
RT @JFreemanDaily: @BrendonStilesMD Lookit that lovely KRAS targeted therapy waterfall plot! Hopeful. #LCSM
Dr Riyaz Shah @DrRiyazShah
T2: ORR for sotorasib feels a bit low but low rate of TRAE DR's was also low. Its a v exciting time and many more KRASi will come along hitting all sorts of different mutations. Its going to just add to an already v complex pathway. #LCSM
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@ProjectBreath @HenningWillers @BrendonStilesMD @HemOncToday Unlike single oncogene driven tumors, KRAS MT tumors often have other co-occuring mutations and complex tumor microenviroment interplay may reduce sensitivity to TKIs #LCSM
Eric Bernicker @EricBernicker
@BrendonStilesMD Significant benefit of immunotherapy in Meso and exciting clarification of molecular sub-classification in small cell that could really facilitate better trials #LCSM
Brendon Stiles @BrendonStilesMD
T3. Still a long way to go for this terrible disease, but Nivolumab improved overall survival, specifically for the epithelioid subtype. #lcsm https://t.co/9Upt4PEf2F
Dave Bjork @bjork5
This is amazing! #research #liquidbiopsy #LCSM
#LCSM Chat @lcsmchat
Hey @Tricia_Braun! Hope you’re doing well. #lcsm
Brendon Stiles @BrendonStilesMD
T3. Still have to determine how best to handle first line treatment and to identify predictors of response. From @DrJNaidoo #lcsm https://t.co/8XdDcY2RPA
#LCSM Chat @lcsmchat
RT @DrRiyazShah: T2: ORR for sotorasib feels a bit low but low rate of TRAE DR's was also low. Its a v exciting time and many more KRASi wi…
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: @ProjectBreath @HenningWillers @BrendonStilesMD @HemOncToday Unlike single oncogene driven tumors, KRAS MT tumors ofte…
#LCSM Chat @lcsmchat
RT @EricBernicker: @BrendonStilesMD Significant benefit of immunotherapy in Meso and exciting clarification of molecular sub-classification…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Still a long way to go for this terrible disease, but Nivolumab improved overall survival, specifically for the e…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Still have to determine how best to handle first line treatment and to identify predictors of response. From @Dr
Dave Bjork @bjork5
This! 👇👇👇 #lcsm @kRasKickers
Sue McCullough @SueMcCu30398663
#LCSM the photo, not mine oneis my cat Tess.
Brendon Stiles @BrendonStilesMD
T3. Several great talks on small cell lung cancer as well. #lcsm From @BenLok https://t.co/GXtY9ljAOX
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Awful #lcsm
Brendon Stiles @BrendonStilesMD
T3. Most exciting to me was @LaurenByersMD lecture on the path forward to precision medicine for small cell lung cancer. #lcsm https://t.co/se4kFIxJmE
Matt Galsky @MattGalsky
RT @DDoroshow: Kudos to @SheenaBhallaMD, representing our #CCOS research group @AACR today in her talk on pandemic-related care disruption…
Jill Feldman @jillfeldman4
T3 I thought the data on the high rates of pathologic germline mutations in #SCLC were very interesting! 67%! Interested in seeing more studies #LCSM
Christine Qiong Wu @wi_qiong
@DrRiyazShah How far is blood and urine breath... for testing lung cancer? #LCSM @DrRiyazShah
Linnea Olson @1111linno
T3 So wild. I've been around since 2005 when there was nothing for NSCLC either. 3 strikes--you were out. We have made some progress. #lcsm
Henning Willers, MD @HenningWillers
RT @BrendonStilesMD: T3. Most exciting to me was @LaurenByersMD lecture on the path forward to precision medicine for small cell lung canc…
Tricia Braun @Tricia_Braun
@lcsmchat I am, thanks! Hope you all are well, too! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Several great talks on small cell lung cancer as well. #lcsm From @BenLok https://t.co/GXtY9ljAOX
Dr Riyaz Shah @DrRiyazShah
T3 #mesothelioma. CONFIRM for me confirmed CPI is active. Combined with PROMISE, in relapsed setting it looks like vinorelbine equiv to single agent CPI. Interesting but we are moving to 1st line Nivo-ipi so will become historical interest soon. #LCSM
Dave Bjork @bjork5
💯 #lcsm #PrecisionMedicine
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Most exciting to me was @LaurenByersMD lecture on the path forward to precision medicine for small cell lung canc…
Brendon Stiles @BrendonStilesMD
T3. Also intriguing, was the presentation on germline mutations in #SCLC. Iz this a heritable disease? https://t.co/4mR8Kuc8tt #lcsm
#LCSM Chat @lcsmchat
RT @jillfeldman4: T3 I thought the data on the high rates of pathologic germline mutations in #SCLC were very interesting! 67%! Interested…
#LCSM Chat @lcsmchat
RT @wi_qiong: @DrRiyazShah How far is blood and urine breath... for testing lung cancer? #LCSM @DrRiyazShah
#LCSM Chat @lcsmchat
RT @1111linno: T3 So wild. I've been around since 2005 when there was nothing for NSCLC either. 3 strikes--you were out. We have made some…
#LCSM Chat @lcsmchat
RT @DrRiyazShah: T3 #mesothelioma. CONFIRM for me confirmed CPI is active. Combined with PROMISE, in relapsed setting it looks like vinorel…
Brendon Stiles @BrendonStilesMD
T3. Other novel combinations showing potential including lurbinectedin + irinotecan #lcsm https://t.co/8mff2eTUTt
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Also intriguing, was the presentation on germline mutations in #SCLC. Iz this a heritable disease? https://t.co…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Other novel combinations showing potential including lurbinectedin + irinotecan #lcsm https://t.co/8mff2eTUTt
Tricia Braun @Tricia_Braun
RT @StephenVLiu: @BrendonStilesMD T1: And CT is not our only screening tool. I’m very optimistic that we will be using blood-based screenin…
Linnea Olson @1111linno
T3 But never enough ;) #lcsm
Eric Bernicker @EricBernicker
@BrendonStilesMD @LaurenByersMD Agree this is very exciting and valuable work #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
More needed with #mesothelioma. Unfortunately it has been generally unresponsive to molecular and immune based therapies. #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: T3. The CONFIRM trial assessed Nivolumab in relapsed mesothelioma. #lcsm From @DrRiyazShah https://t.co/ZqNPtLVmNv
Dave Bjork @bjork5
@n8pennell This is so promising! 🙏🏽 #lcsm #kras #PrecisionMedicine
Brendon Stiles @BrendonStilesMD
Where is @jillfeldman4? T4 coming next! #lcsm
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: More needed with #mesothelioma. Unfortunately it has been generally unresponsive to molecular and immune based therapies.…
Brendon Stiles @BrendonStilesMD
T4. How can we make clinical trials better and more patient centric? #lcsm
Stacey Tinianov @coffeemommy
@1111linno YES! And in large part to your (and many others') willingness to contribute to research. #lcsm Thank you, my friend. (Wish I could thank you with a vaccine 💗 and a hug!)
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. How can we make clinical trials better and more patient centric? #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
#LiquidBiopsy #lcsm
Dave Bjork @bjork5
Again, this! 👇 #LCSM #research
Sara Whitlock @sjwhitlock
T4. Early involvement!!!#LCSM
Brendon Stiles @BrendonStilesMD
T4. Key to think about the patient perspective from the very beginning of trial design. #lcsm
Linnea Olson @1111linno
T4 I got here just in time. Talk to patients, listen, compensate them. For a start... #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Key to think about the patient perspective from the very beginning of trial design. #lcsm
#LCSM Chat @lcsmchat
RT @sjwhitlock: T4. Early involvement!!!#LCSM
Determined to Cure @determined2cure
The #determinedtocure Daily is out! #d2c https://t.co/LzlvU709G6 Stories via @LizSzabo #lcsm #wclc20
#LCSM Chat @lcsmchat
RT @1111linno: T4 I got here just in time. Talk to patients, listen, compensate them. For a start... #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Need to work hard to get past surgical therapy. #lcsm
Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh
RT @1111linno: T4 I got here just in time. Talk to patients, listen, compensate them. For a start... #lcsm
Brendon Stiles @BrendonStilesMD
T4. As @jillfeldman4 suggested, if we “fit” the trial only to the “correct” patients we may learn very little. #lcsm https://t.co/mSghvVJZ8B
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: Need to work hard to get past surgical therapy. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. As @jillfeldman4 suggested, if we “fit” the trial only to the “correct” patients we may learn very little. #lcsm
Mark B In SD @MomsOopsBaby
RT @1111linno: T3 So wild. I've been around since 2005 when there was nothing for NSCLC either. 3 strikes--you were out. We have made some…
Sara Whitlock @sjwhitlock
T4. Jill has said it best. What is important to the researcher not always same to the patient. #LCSM
Jill Feldman @jillfeldman4
T4 The patients voice needs to be at the core of the study design to make sure that research questions are centered around what patients need, not just what researchers want. There needs to be a shift from creating trials for us, to creating trials with us. #LCSM https://t.co/XSfjVFsAoo
Brendon Stiles @BrendonStilesMD
T4. We should be able to expand eligibility. #lcsm https://t.co/HhmFahchcj
Lillian Leigh @ProjectBreath
T4. This 👇. That's how! @jillfeldman4 #LCSM
Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh
@jillfeldman4 Well said #lcsm
Sara Whitlock @sjwhitlock
T4. Expand inclusion criteria #LCSM
Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh
RT @jillfeldman4: T4 The patients voice needs to be at the core of the study design to make sure that research questions are centered aroun…
Dave Bjork @bjork5
@HemOncToday @IASLC @sloan_kettering @MMarmarelis @Penn Impressive! #lcsm @BrendonStilesMD @CharuAggarwalMD
#LCSM Chat @lcsmchat
RT @sjwhitlock: T4. Jill has said it best. What is important to the researcher not always same to the patient. #LCSM
Henning Willers, MD @HenningWillers
RT @jillfeldman4: T4 The patients voice needs to be at the core of the study design to make sure that research questions are centered aroun…
#LCSM Chat @lcsmchat
RT @jillfeldman4: T4 The patients voice needs to be at the core of the study design to make sure that research questions are centered aroun…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. We should be able to expand eligibility. #lcsm https://t.co/HhmFahchcj
Jill Feldman @jillfeldman4
T4 There are multiple, and important, stakeholders in both the drug development lifecycle and the patient journey, but only patients and caregivers are impacted by every decision made from the beginning and throughout the entire process. Yet, not always included! #LCSM https://t.co/nwPAF1c7u1
#LCSM Chat @lcsmchat
RT @ProjectBreath: T4. This 👇. That's how! @jillfeldman4 #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Small cell carcinoma is a high grade neuroendocrine cancer. Historically terrible outcomes with most patients. #lcsm
#LCSM Chat @lcsmchat
RT @sjwhitlock: T4. Expand inclusion criteria #LCSM
Sue McCullough @SueMcCu30398663
#LCSM Advocates as apart of the trial design!
mimiprovenzano @MimiProvenzano
RT @jillfeldman4: T4 The patients voice needs to be at the core of the study design to make sure that research questions are centered aroun…
#LCSM Chat @lcsmchat
RT @jillfeldman4: T4 There are multiple, and important, stakeholders in both the drug development lifecycle and the patient journey, but on…
Brendon Stiles @BrendonStilesMD
T4. @iaslc has done a good job taking lead on addressing this. #lcsm https://t.co/uuzTDdjN33
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: Small cell carcinoma is a high grade neuroendocrine cancer. Historically terrible outcomes with most patients. #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: T3. Most exciting to me was @LaurenByersMD lecture on the path forward to precision medicine for small cell lung canc…
Linnea Olson @1111linno
T4 I had to pay out of pocket costs today for drug to combat side effects of clinical trial drug. Why would sponsor not pick up cost? #lcsm
#LCSM Chat @lcsmchat
RT @SueMcCu30398663: #LCSM Advocates as apart of the trial design!
Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh
@SueMcCu30398663 Oh Sue great pic #LCSM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. @iaslc has done a good job taking lead on addressing this. #lcsm https://t.co/uuzTDdjN33
#LCSM Chat @lcsmchat
RT @1111linno: T4 I had to pay out of pocket costs today for drug to combat side effects of clinical trial drug. Why would sponsor not pick…
Jonathan Spicer MD PhD @DoctorJSpicer
@BrendonStilesMD @HenningWillers @HemOncToday @molina_arcas And obviously with #surgery. Doesn’t prehabilitation and pill before going for curative surgery sound good? So many opportunities to learn patterns of resistance and confirm immunological effects of this targeted therapy either alone or combined with other agents #lcsm #tssmn
Lillian Leigh @ProjectBreath
RT @BrendonStilesMD: T4. @iaslc has done a good job taking lead on addressing this. #lcsm https://t.co/uuzTDdjN33
Herbert Loong @herbloong
RT @BrendonStilesMD: T2. Very good response in these pretreated patients. Questions remain about duration of response. #lcsm From @herbl
Tim Broyle, MD @BroyleTim
RT @jillfeldman4: T4 There are multiple, and important, stakeholders in both the drug development lifecycle and the patient journey, but on…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Go @1111linno! #lcsm
Linnea Olson @1111linno
T4 Talk to patients but talk to the RIGHT patients. Those who have participated in trials. And or been excluded from participation. #lcsm
Brendon Stiles @BrendonStilesMD
T4. Good to discuss and prioritize endpoints important to patients – survival, recurrence, quality of life. It is what is important to them, not so much us. #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @DrRiyazShah: T3 #mesothelioma. CONFIRM for me confirmed CPI is active. Combined with PROMISE, in relapsed setting it looks like vinorel…
mimiprovenzano @MimiProvenzano
RT @TimAllenMDJD: Small cell carcinoma is a high grade neuroendocrine cancer. Historically terrible outcomes with most patients. #lcsm ht…
Peggy Dennis @peggyddennis
T4 - Expand to driver mutations across different cancer types. I.e. breast/ lung/gastric. Lots of data #lcsm
Stacey Tinianov @coffeemommy
@BrendonStilesMD Rhetorical question for this crowd. Perhaps a better question is HOW do we take the obvious answer of "involve patients!" and share it in a way to influence the larger healthcare/cancercare/research ecosystem? #lcsm #hcldr
LungCancer.net @LungCancer_HU
RT @jillfeldman4: T4 The patients voice needs to be at the core of the study design to make sure that research questions are centered aroun…
Dave Bjork @bjork5
@1111linno T4 great timing for your entrance! #lcsm #patients 💯💯💯💯
Brendon Stiles @BrendonStilesMD
T4. Also important to acknowledge the role patients play in every advance we make. #lcsm From @ProjectBreath https://t.co/j6eDKPc4sV
Lillian Leigh @ProjectBreath
@BrendonStilesMD @IASLC Yes, thank you to @IASLC for taking the lead. Same with @globalungcancer as well. We desperately need to change the status quo! #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: T3. Also intriguing, was the presentation on germline mutations in #SCLC. Iz this a heritable disease? https://t.co…
benjamin wu @benjaminwumd
RT @DrRiyazShah: T3 #mesothelioma. CONFIRM for me confirmed CPI is active. Combined with PROMISE, in relapsed setting it looks like vinorel…
Jill Feldman @jillfeldman4
T4 The #1 restrictive eligibility criteria is #HEALTHDISPARITIES! Broadening eligibility criteria will only go so far and doesn't adress the fact that people in under resourced communities don't participate because they aren't aware and/or not asked! #LCSM https://t.co/rRfazYT5yk
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: T3. Other novel combinations showing potential including lurbinectedin + irinotecan #lcsm https://t.co/8mff2eTUTt
Lillian Leigh @ProjectBreath
RT @BrendonStilesMD: T4. Also important to acknowledge the role patients play in every advance we make. #lcsm From @ProjectBreath https://…
Dr Riyaz Shah @DrRiyazShah
T4: Patient voice must always be central. I'm convinced the profession is listening. 10y ago the major criticism was the long length in drug dev cycles before patients got access. This is much shorter now. #LCSM
Sara Whitlock @sjwhitlock
T4. Also improve PROs. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @DrRiyazShah: T3 #mesothelioma. CONFIRM for me confirmed CPI is active. Combined with PROMISE, in relapsed setting it looks like vinorel…
Brendon Stiles @BrendonStilesMD
T4. Another great point from @jillfeldman4 regarding need for real world data. #lcsm https://t.co/nzbwpqvNtI
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @jillfeldman4: T4 There are multiple, and important, stakeholders in both the drug development lifecycle and the patient journey, but on…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. Also intriguing, was the presentation on germline mutations in #SCLC. Iz this a heritable disease? https://t.co…
Jonathan Spicer MD PhD @DoctorJSpicer
@BrendonStilesMD More changed for the better of mesothelioma patients in the last year than in the prior 20! Can’t wait to see how this fits with potentially operable patients. #lcsm #tssmn
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. Other novel combinations showing potential including lurbinectedin + irinotecan #lcsm https://t.co/8mff2eTUTt
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @SueMcCu30398663: #LCSM Advocates as apart of the trial design!
Janet Freeman-Daily @JFreemanDaily
RT @EricBernicker: @BrendonStilesMD @LaurenByersMD Agree this is very exciting and valuable work #LCSM
Brendon Stiles @BrendonStilesMD
T4. And a great talk at the earlier #WCLC20 meeting from @JFreemanDaily on modernizing clinical trials. #lcsm https://t.co/FETEC3m3zi
#LCSM Chat @lcsmchat
RT @DoctorJSpicer: @BrendonStilesMD @HenningWillers @HemOncToday @molina_arcas And obviously with #surgery. Doesn’t prehabilitation and pil…
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: More needed with #mesothelioma. Unfortunately it has been generally unresponsive to molecular and immune based therapies.…
#LCSM Chat @lcsmchat
RT @1111linno: T4 Talk to patients but talk to the RIGHT patients. Those who have participated in trials. And or been excluded from partici…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Good to discuss and prioritize endpoints important to patients – survival, recurrence, quality of life. It is wh…
Dave Bjork @bjork5
@jillfeldman4 Volunteers are VIPs #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. How can we make clinical trials better and more patient centric? #lcsm
#LCSM Chat @lcsmchat
RT @peggyddennis: T4 - Expand to driver mutations across different cancer types. I.e. breast/ lung/gastric. Lots of data #lcsm
#LCSM Chat @lcsmchat
RT @coffeemommy: @BrendonStilesMD Rhetorical question for this crowd. Perhaps a better question is HOW do we take the obvious answer of "in…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Also important to acknowledge the role patients play in every advance we make. #lcsm From @ProjectBreath https://…
#LCSM Chat @lcsmchat
RT @ProjectBreath: @BrendonStilesMD @IASLC Yes, thank you to @IASLC for taking the lead. Same with @globalungcancer as well. We desperately…
Brendon Stiles @BrendonStilesMD
@coffeemommy Definitely deserving of an in depth discussion. #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
We MUST continue to address! #lcsm
Lillian Leigh @ProjectBreath
RT @BrendonStilesMD: T4. And a great talk at the earlier #WCLC20 meeting from @JFreemanDaily on modernizing clinical trials. #lcsm https:…
#LCSM Chat @lcsmchat
RT @jillfeldman4: T4 The #1 restrictive eligibility criteria is #HEALTHDISPARITIES! Broadening eligibility criteria will only go so far and…
#LCSM Chat @lcsmchat
RT @DrRiyazShah: T4: Patient voice must always be central. I'm convinced the profession is listening. 10y ago the major criticism was the l…
#LCSM Chat @lcsmchat
RT @sjwhitlock: T4. Also improve PROs. #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @DoctorJSpicer: @BrendonStilesMD @HenningWillers @HemOncToday @molina_arcas And obviously with #surgery. Doesn’t prehabilitation and pil…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Another great point from @jillfeldman4 regarding need for real world data. #lcsm https://t.co/nzbwpqvNtI
#LCSM Chat @lcsmchat
RT @DoctorJSpicer: @BrendonStilesMD More changed for the better of mesothelioma patients in the last year than in the prior 20! Can’t wait…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. And a great talk at the earlier #WCLC20 meeting from @JFreemanDaily on modernizing clinical trials. #lcsm https:…
Brendon Stiles @BrendonStilesMD
RT @ProjectBreath: @BrendonStilesMD @IASLC Yes, thank you to @IASLC for taking the lead. Same with @globalungcancer as well. We desperately…
#LCSM Chat @lcsmchat
RT @bjork5: @jillfeldman4 Volunteers are VIPs #lcsm
Lillian Leigh @ProjectBreath
RT @jillfeldman4: T4 The #1 restrictive eligibility criteria is #HEALTHDISPARITIES! Broadening eligibility criteria will only go so far and…
Linnea Olson @1111linno
T4 Understand and discuss barriers to participation. Preexisting conditions but also personal expense. $, time, emotional, physical. #lcsm
Brendon Stiles @BrendonStilesMD
This.... #lcsm
Christine Qiong Wu @wi_qiong
RT @1111linno: T4 I got here just in time. Talk to patients, listen, compensate them. For a start... #lcsm
Dr. Amy C. Moore @acmoorephd
Sorry I'm late to the party #LCSM
#LCSM Chat @lcsmchat
RT @1111linno: T4 Understand and discuss barriers to participation. Preexisting conditions but also personal expense. $, time, emotional, p…
Jill Feldman @jillfeldman4
T4 I think it also STARTS WITH THE FUNDER. If the requirements are in the funding opportunity then the proposals will be written to include those requirements, which means they will be in the protocol & so on. #LCSM
Matthew Smeltzer @MattSmeltzer
RT @TimAllenMDJD: We MUST continue to address! #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
#QualityOfLife is too often overlooked or minimized. #lcsm
kristen kimball @KimballKristen
@jillfeldman4 thank you for caregiver inclusion #lcsm
Dr. Amy C. Moore @acmoorephd
RT @jillfeldman4: T4 The patients voice needs to be at the core of the study design to make sure that research questions are centered aroun…
Brendon Stiles @BrendonStilesMD
Homestretch....T5 coming up. #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @coffeemommy: @BrendonStilesMD Rhetorical question for this crowd. Perhaps a better question is HOW do we take the obvious answer of "in…
Stacey Tinianov @coffeemommy
@jillfeldman4 So much this! 🎉 Across clinical trials, cancer care, supportive care and then across ALL of heath care. Designing "for" patients was so 2000s. We need to design WITH patients & their families. #lcsm #bcsm #crcsm #gyncsm #pancsm #cancerresearch #WorldCancerDay
#LCSM Chat @lcsmchat
RT @jillfeldman4: T4 I think it also STARTS WITH THE FUNDER. If the requirements are in the funding opportunity then the proposals will be…
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: #QualityOfLife is too often overlooked or minimized. #lcsm
KRASKickers @kRasKickers
RT @BrendonStilesMD: This.... #lcsm https://t.co/juca7KhUC2
Janet Freeman-Daily @JFreemanDaily
T4: We need to remove barriers to #clinicaltrial participation to achieve #equity in enrollment--need to eliminate disparities in age, income, socioeconomic factors. #LCSM https://t.co/k6w69irIwB
Linnea Olson @1111linno
T4 Change the language. Scratch noncompliant. And volunteer. I am not a fucking volunteer. Cancer chose me and I was desperate. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: We MUST continue to address! #lcsm https://t.co/yZC02tDxLp
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
#PatientsFirst #lcsm
#LCSM Chat @lcsmchat
RT @coffeemommy: @jillfeldman4 So much this! 🎉 Across clinical trials, cancer care, supportive care and then across ALL of heath care. Desi…
Janet Freeman-Daily @JFreemanDaily
RT @1111linno: T4 Understand and discuss barriers to participation. Preexisting conditions but also personal expense. $, time, emotional, p…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @jillfeldman4: T4 The #1 restrictive eligibility criteria is #HEALTHDISPARITIES! Broadening eligibility criteria will only go so far and…
KRASKickers @kRasKickers
RT @BrendonStilesMD: T4. And a great talk at the earlier #WCLC20 meeting from @JFreemanDaily on modernizing clinical trials. #lcsm https:…
Brendon Stiles @BrendonStilesMD
T5. How can we improve access to and affordability of lung cancer care? #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
RT @JFreemanDaily: T4: We need to remove barriers to #clinicaltrial participation to achieve #equity in enrollment--need to eliminate dispa…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: This.... #lcsm https://t.co/juca7KhUC2
Janet Freeman-Daily @JFreemanDaily
RT @jillfeldman4: T4 I think it also STARTS WITH THE FUNDER. If the requirements are in the funding opportunity then the proposals will be…
Matthew Smeltzer @MattSmeltzer
Agree! Including selection of endpoints
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T4: We need to remove barriers to #clinicaltrial participation to achieve #equity in enrollment--need to eliminate dispa…
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: #QualityOfLife is too often overlooked or minimized. #lcsm https://t.co/uEfafwxSQ5
Brendon Stiles @BrendonStilesMD
T5. With so many dramatic improvements in screening, diagnosis, and tailored treatment, we have to make sure that they are available to all patients. #lcsm
#LCSM Chat @lcsmchat
RT @1111linno: T4 Change the language. Scratch noncompliant. And volunteer. I am not a fucking volunteer. Cancer chose me and I was despera…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: T4. Another great point from @jillfeldman4 regarding need for real world data. #lcsm https://t.co/nzbwpqvNtI
Dr. Amy C. Moore @acmoorephd
As @jillfeldman4 said in her #WCLC20 talk, let's not forget the 80% of patients under water #lcsm @IASLC
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. How can we improve access to and affordability of lung cancer care? #lcsm
Inspire @teaminspire
RT @BrendonStilesMD: T5. How can we improve access to and affordability of lung cancer care? #lcsm
Lillian Leigh @ProjectBreath
Taking this opportunity to acknowledge the wonderful work that many in Australia are doing in this space - @NicStraiton @cancer_K2A @CancerSPHERE @ACTA_org @hagsie @COSA_Surviv and so many more (please tag!) #LCSM
KRASKickers @kRasKickers
RT @DrRiyazShah: T4: Patient voice must always be central. I'm convinced the profession is listening. 10y ago the major criticism was the l…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. With so many dramatic improvements in screening, diagnosis, and tailored treatment, we have to make sure that the…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @DoctorJSpicer: @BrendonStilesMD More changed for the better of mesothelioma patients in the last year than in the prior 20! Can’t wait…
Tricia Braun @Tricia_Braun
RT @lgreco_ny: On this #worldcancerday please remember all of the millions of cancer patients being denied the #CovidVaccine, which for the…
#LCSM Chat @lcsmchat
RT @acmoorephd: As @jillfeldman4 said in her #WCLC20 talk, let's not forget the 80% of patients under water #lcsm @IASLC
Hiroaki Akamatsu @AkamatsuHiroaki
RT @CharuAggarwalMD: Capmatinib shows modest efficacy in patients with MET alterations treated with crizotinib Obj RR ~ 10% https://t.co/2…
Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh
RT @1111linno: T4 Understand and discuss barriers to participation. Preexisting conditions but also personal expense. $, time, emotional, p…
#LCSM Chat @lcsmchat
RT @ProjectBreath: Taking this opportunity to acknowledge the wonderful work that many in Australia are doing in this space - @NicStraiton
Brendon Stiles @BrendonStilesMD
T5. Literacy is one key element. #lcsm From @jillfeldman4 https://t.co/fkwt26LjXJ
Sara Whitlock @sjwhitlock
T5. Must decentralize. #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
@JFreemanDaily, #lcsm superstar!
Linnea Olson @1111linno
T5 Bring it to the patient instead of expecting the patient to come to it. Telehealth but also informed local oncologists. #lcsm
Janet Freeman-Daily @JFreemanDaily
@TimAllenMDJD Yes, need #cancer #clinicaltrial PROs (patient reported outcomes) that measure #QoL (quality of life) that matters to the PATIENT, tailored to the disease and type of treatment. #LCSM
Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh
@1111linno Need to learn patient perspective and commitment #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @coffeemommy: @jillfeldman4 So much this! 🎉 Across clinical trials, cancer care, supportive care and then across ALL of heath care. Desi…
Brendon Stiles @BrendonStilesMD
T5. Not all is lost. Even our highest risk patients have shown some improvements. #lcsm Work I presented at #wclc20 https://t.co/qdBTUATm4R
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Literacy is one key element. #lcsm From @jillfeldman4 https://t.co/fkwt26LjXJ
#LCSM Chat @lcsmchat
RT @sjwhitlock: T5. Must decentralize. #LCSM
Dr Riyaz Shah @DrRiyazShah
T4: But we must never stop learning and improving. There is lots wrong. Big Pharma have too much say in trial design, eligibility criteria. Too easy to game the system. However, without their sheer financial clout we would be in the slow lane. #LCSM
#LCSM Chat @lcsmchat
RT @1111linno: T5 Bring it to the patient instead of expecting the patient to come to it. Telehealth but also informed local oncologists.…
Jill Feldman @jillfeldman4
T4 Only the patients & communities know what they need, what their barriers are & how to make a trial accessible and successful for them. As 'Who is NOT at the table' starting at R & D #LCSM
Hiroaki Akamatsu @AkamatsuHiroaki
RT @JackWestMD: A day w/o debate on #ADAURA is like a day w/o☀️, so I'll highlight new viewpoint by @oncology_bg & myself in @JAMAOnc on "W…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @TimAllenMDJD Yes, need #cancer #clinicaltrial PROs (patient reported outcomes) that measure #QoL (quality of life) that…
Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh
RT @sjwhitlock: T5. Must decentralize. #LCSM
#LCSM Chat @lcsmchat
RT @Kamacintosh: @1111linno Need to learn patient perspective and commitment #LCSM
Brendon Stiles @BrendonStilesMD
T5. In fact, I was pleased to see that @iaslc #WCLC20 devoted a whole press conference to addressing disparities. #lcsm https://t.co/rFvclJ7SSn
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: #PatientsFirst #lcsm https://t.co/AorQl0isa8
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Not all is lost. Even our highest risk patients have shown some improvements. #lcsm Work I presented at #wclc20
Dave Bjork @bjork5
“Do what’s right, not what’s easy” #LCSM @CraigLipset @joedustin @jillfeldman4 @stales @Medidata @DaveFuehrer @ctraz @LaurenMachos @CaptainClinical #patients #clinicaltrials
#LCSM Chat @lcsmchat
RT @DrRiyazShah: T4: But we must never stop learning and improving. There is lots wrong. Big Pharma have too much say in trial design, elig…
#LCSM Chat @lcsmchat
RT @jillfeldman4: T4 Only the patients & communities know what they need, what their barriers are & how to make a trial accessible and succ…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. How can we improve access to and affordability of lung cancer care? #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. In fact, I was pleased to see that @iaslc #WCLC20 devoted a whole press conference to addressing disparities. #…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. With so many dramatic improvements in screening, diagnosis, and tailored treatment, we have to make sure that the…
Brendon Stiles @BrendonStilesMD
T5. Certainly, we have to work harder to bring lung cancer screening to all. #lcsm
Jill Feldman @jillfeldman4
T4 The most important 'End Point' in a trial is the patient! #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @ProjectBreath: Taking this opportunity to acknowledge the wonderful work that many in Australia are doing in this space - @NicStraiton
KRASKickers @kRasKickers
RT @BrendonStilesMD: T4. As @jillfeldman4 suggested, if we “fit” the trial only to the “correct” patients we may learn very little. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. Literacy is one key element. #lcsm From @jillfeldman4 https://t.co/fkwt26LjXJ
LungCancer.net @LungCancer_HU
RT @BrendonStilesMD: T5. With so many dramatic improvements in screening, diagnosis, and tailored treatment, we have to make sure that the…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Certainly, we have to work harder to bring lung cancer screening to all. #lcsm
KRASKickers @kRasKickers
RT @bjork5: @n8pennell This is so promising! 🙏🏽 #lcsm #kras #PrecisionMedicine
Brendon Stiles @BrendonStilesMD
T5. And once diagnosed, access to comprehensive biomarker testing for ALL patients is critical. #lcsm
#LCSM Chat @lcsmchat
RT @jillfeldman4: T4 The most important 'End Point' in a trial is the patient! #LCSM
Nathan A. Pennell MD, PhD, FASCO @n8pennell
T5. Hard to imagine everyone having access to these exciting therapies unless something is done about drug costs. Some $20k/month now and goes up annually #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: @JFreemanDaily, #lcsm superstar! https://t.co/gmpjxD5Nms
KRASKickers @kRasKickers
RT @bjork5: 💯 #lcsm #PrecisionMedicine https://t.co/B25XhZRQbO
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Rural and inner city patients. Racial minorities. LGBTQ. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @JFreemanDaily: @TimAllenMDJD Yes, need #cancer #clinicaltrial PROs (patient reported outcomes) that measure #QoL (quality of life) that…
Eric Bernicker @EricBernicker
@BrendonStilesMD Yes! But maybe this is the hardest ask of all... Much of the discussions we have on inpatient rounds these days center on dealing with patients with no insurance or who are out of network or who have little family support #LCSM
Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh
RT @BrendonStilesMD: T5. And once diagnosed, access to comprehensive biomarker testing for ALL patients is critical. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. And once diagnosed, access to comprehensive biomarker testing for ALL patients is critical. #lcsm
Jill Feldman @jillfeldman4
T5 We have the data, we know there's a problem. We need to stop describing and start ‘actionizing’ Indifference and silence only perpetuates injustice. EVERYONE needs to do their part #LCSM
virginia litle @vlitlemd
T5 access to screening for all (underserved) takes educating those who fear stigma of cancer/screening #lcsm
#LCSM Chat @lcsmchat
RT @n8pennell: T5. Hard to imagine everyone having access to these exciting therapies unless something is done about drug costs. Some $20k/…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. Not all is lost. Even our highest risk patients have shown some improvements. #lcsm Work I presented at #wclc20
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @jillfeldman4: T4 I think it also STARTS WITH THE FUNDER. If the requirements are in the funding opportunity then the proposals will be…
Linnea Olson @1111linno
T5 Cancer is not fair. Access to care is not fair. Support systems are not all equal. We must do what we can to address disparity. #lcsm
#LCSM Chat @lcsmchat
RT @TimAllenMDJD: Rural and inner city patients. Racial minorities. LGBTQ. #lcsm
#LCSM Chat @lcsmchat
RT @EricBernicker: @BrendonStilesMD Yes! But maybe this is the hardest ask of all... Much of the discussions we have on inpatient rounds th…
#LCSM Chat @lcsmchat
RT @jillfeldman4: T5 We have the data, we know there's a problem. We need to stop describing and start ‘actionizing’ Indifference and silen…
Janet Freeman-Daily @JFreemanDaily
RT @DrRiyazShah: T4: But we must never stop learning and improving. There is lots wrong. Big Pharma have too much say in trial design, elig…
Janet Freeman-Daily @JFreemanDaily
RT @jillfeldman4: T4 Only the patients & communities know what they need, what their barriers are & how to make a trial accessible and succ…
#LCSM Chat @lcsmchat
RT @vlitlemd: T5 access to screening for all (underserved) takes educating those who fear stigma of cancer/screening #lcsm
Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh
RT @1111linno: T5 Cancer is not fair. Access to care is not fair. Support systems are not all equal. We must do what we can to address disp…
#LCSM Chat @lcsmchat
RT @1111linno: T5 Cancer is not fair. Access to care is not fair. Support systems are not all equal. We must do what we can to address disp…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. In fact, I was pleased to see that @iaslc #WCLC20 devoted a whole press conference to addressing disparities. #…
Jill Feldman @jillfeldman4
T5 Underserved Communities are defined by multiple constructs – The LGBTQ+, elderly, people who live in rural communities and other groups also face disparities and barriers and need to be represented. #LCSM
Brendon Stiles @BrendonStilesMD
T5. On the other hand financial toxicity has been widely discussed and is real. Need to work with hospital systems, insurance, and industry to seriously address. #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
RT @jillfeldman4: T4 Only the patients & communities know what they need, what their barriers are & how to make a trial accessible and succ…
Janet Freeman-Daily @JFreemanDaily
RT @bjork5: “Do what’s right, not what’s easy” #LCSM @CraigLipset @joedustin @jillfeldman4 @stales @Medidata @DaveFuehrer @ctraz @LaurenMac
Jamie Holloway, PhD @jamienholloway
@jillfeldman4 I had this conversation with an early career oncologist a few years ago. They’ve not the ones writing the big protocols. It’s the sponsors. So glad they are listening more now, too. #lcsm
Nirmal Raut @oncologician
@BrendonStilesMD T5 .If there is no clinical trial in any country ,at least an expanded access should be mandatory #lcsm
#LCSM Chat @lcsmchat
RT @jillfeldman4: T5 Underserved Communities are defined by multiple constructs – The LGBTQ+, elderly, people who live in rural communities…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
#equity #NoStigma #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. Certainly, we have to work harder to bring lung cancer screening to all. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. On the other hand financial toxicity has been widely discussed and is real. Need to work with hospital systems,…
Janet Freeman-Daily @JFreemanDaily
RT @jillfeldman4: T4 The most important 'End Point' in a trial is the patient! #LCSM
Brendon Stiles @BrendonStilesMD
T5. As always, @fumikochino taking the lead on discussions of financial toxicity #lcsm: https://t.co/t1TGC42z7z
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. And once diagnosed, access to comprehensive biomarker testing for ALL patients is critical. #lcsm
Dr Riyaz Shah @DrRiyazShah
@jillfeldman4 T4: Key issue. So many amazing and relevant trials in lung cancer have been shelved due to funders not thinking it was worthy. Big issue in UK. Disheartening for investigators to work up a trial with a huge team to then have it pulled by a funding body #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @n8pennell: T5. Hard to imagine everyone having access to these exciting therapies unless something is done about drug costs. Some $20k/…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: T5. Not all is lost. Even our highest risk patients have shown some improvements. #lcsm Work I presented at #wclc20
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: Rural and inner city patients. Racial minorities. LGBTQ. #lcsm https://t.co/ovffKGDzSV
Linnea Olson @1111linno
T5 Lack of information/access is an issue but so is lack of resources. And fear. We must help each other out. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @EricBernicker: @BrendonStilesMD Yes! But maybe this is the hardest ask of all... Much of the discussions we have on inpatient rounds th…
Lillian Leigh @ProjectBreath
T5. Boy, there's so much that we can do... tweets only allow 280 characters! #LCSM
Brendon Stiles @BrendonStilesMD
T5. And from @DevikaDasMD #lcsm https://t.co/ounoFtDJpr
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: T5. In fact, I was pleased to see that @iaslc #WCLC20 devoted a whole press conference to addressing disparities. #…
Janet Freeman-Daily @JFreemanDaily
RT @jillfeldman4: T5 We have the data, we know there's a problem. We need to stop describing and start ‘actionizing’ Indifference and silen…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @bjork5: “Do what’s right, not what’s easy” #LCSM @CraigLipset @joedustin @jillfeldman4 @stales @Medidata @DaveFuehrer @ctraz @LaurenMac
Janet Freeman-Daily @JFreemanDaily
RT @vlitlemd: T5 access to screening for all (underserved) takes educating those who fear stigma of cancer/screening #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @1111linno: T5 Cancer is not fair. Access to care is not fair. Support systems are not all equal. We must do what we can to address disp…
Breast Advocate @BreastAdvocate
RT @DrAttai: Re-addressing needs of cancer survivors during #COVID19 @DrN_CancerPCP et al in @JNCI_Now https://t.co/0ZZEOqohDB #bcsm #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @jillfeldman4: T5 Underserved Communities are defined by multiple constructs – The LGBTQ+, elderly, people who live in rural communities…
Nathan A. Pennell MD, PhD, FASCO @n8pennell
T5. This! I’d like to see a fraction of $ spent on drugs applied to getting every single eligible patient tested worldwide #LCSM
#LCSM Chat @lcsmchat
RT @jamienholloway: @jillfeldman4 I had this conversation with an early career oncologist a few years ago. They’ve not the ones writing the…
#LCSM Chat @lcsmchat
RT @oncologician: @BrendonStilesMD T5 .If there is no clinical trial in any country ,at least an expanded access should be mandatory #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. On the other hand financial toxicity has been widely discussed and is real. Need to work with hospital systems,…
Jill Feldman @jillfeldman4
T5 Collaborate with community hospitals and minority physicians – physicians are a trusted voice in the community and people trust people who are more like them. This should be written into funding! #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Word #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @jamienholloway: @jillfeldman4 I had this conversation with an early career oncologist a few years ago. They’ve not the ones writing the…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. As always, @fumikochino taking the lead on discussions of financial toxicity #lcsm: https://t.co/t1TGC42z7z
#LCSM Chat @lcsmchat
RT @DrRiyazShah: @jillfeldman4 T4: Key issue. So many amazing and relevant trials in lung cancer have been shelved due to funders not think…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @EricBernicker: @BrendonStilesMD Yes! But maybe this is the hardest ask of all... Much of the discussions we have on inpatient rounds th…
#LCSM Chat @lcsmchat
RT @1111linno: T5 Lack of information/access is an issue but so is lack of resources. And fear. We must help each other out. #lcsm
Brendon Stiles @BrendonStilesMD
Undoubtedly a major challenge. I am going to jump all over it at @MontefioreNYC and @EinsteinMed #lcsm. This has to change.
Christine Qiong Wu @wi_qiong
@TimAllenMDJD I can't agree more. #QualityOfLife is overlooked. #LCSM @TimAllenMDJD
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. And from @DevikaDasMD #lcsm https://t.co/ounoFtDJpr
#LCSM Chat @lcsmchat
RT @n8pennell: T5. This! I’d like to see a fraction of $ spent on drugs applied to getting every single eligible patient tested worldwide #…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Walk the talk. #lcsm
Brendon Stiles @BrendonStilesMD
T5. #COVID19 has certainly also affected access to care. #lcsm From @LauraMezquitaMD: https://t.co/Kkcq8PUUm9
#StayHome @viralvideovlogs
RT @BrendonStilesMD: T5. #COVID19 has certainly also affected access to care. #lcsm From @LauraMezquitaMD: https://t.co/Kkcq8PUUm9
#LCSM Chat @lcsmchat
RT @jillfeldman4: T5 Collaborate with community hospitals and minority physicians – physicians are a trusted voice in the community and pe…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @jillfeldman4: T5 Underserved Communities are defined by multiple constructs – The LGBTQ+, elderly, people who live in rural communities…
Dr. Openly Excessively Black & Disabled (She/Her) @4WheelWorkOut
#HighRiskNY
Dr Riyaz Shah @DrRiyazShah
T5; Move to the UK. It will be free. You won't have the same access to a named doc caring for you. Have to accept more rationed access to tech...but still reasonable. #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: T5. On the other hand financial toxicity has been widely discussed and is real. Need to work with hospital systems,…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Undoubtedly a major challenge. I am going to jump all over it at @MontefioreNYC and @EinsteinMed #lcsm. This has to c…
Dave Bjork @bjork5
Big issue. I don’t have the answer, but every lung cancer patient deserves access to genomic testing and latests treatments, academic or community setting. @OneOncology @FoundationATCG #lcsm #PrecisionMedicine
#LCSM Chat @lcsmchat
RT @wi_qiong: @TimAllenMDJD I can't agree more. #QualityOfLife is overlooked. #LCSM @TimAllenMDJD
emily.elswick @ElswickEmily
RT @BrendonStilesMD: T5. With so many dramatic improvements in screening, diagnosis, and tailored treatment, we have to make sure that the…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. #COVID19 has certainly also affected access to care. #lcsm From @LauraMezquitaMD: https://t.co/Kkcq8PUUm9
#LCSM Chat @lcsmchat
RT @DrRiyazShah: T5; Move to the UK. It will be free. You won't have the same access to a named doc caring for you. Have to accept more rat…
Sara Whitlock @sjwhitlock
I talk to a lot of newly diagnosed people. Shocked at how many have not had bio marker testing. #lcsm
Janet Freeman-Daily @JFreemanDaily
T5. To address disparities in access to #lungcancer care, need to have ALL the players at the table: patients, disadvantaged community members, providers, researchers, payers, regulatory agencies, pharmacy benefit managers, pharma, biotech, advocates, nonprofits ... #LCSM
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T5. To address disparities in access to #lungcancer care, need to have ALL the players at the table: patients, disadvan…
#LCSM Chat @lcsmchat
RT @sjwhitlock: I talk to a lot of newly diagnosed people. Shocked at how many have not had bio marker testing. #lcsm
Alicia C. Staley @stales
RT @bjork5: “Do what’s right, not what’s easy” #LCSM @CraigLipset @joedustin @jillfeldman4 @stales @Medidata @DaveFuehrer @ctraz @LaurenMac
Lillian Leigh @ProjectBreath
T5. Financial toxicity goes beyond health costs - consequential financial hardship impacts on family relationships, credit and debt, social security and other social hardship. #LCSM
Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh
@BrendonStilesMD @LauraMezquitaMD Delays and fear of going to hospital / can’t assess a patient by phone #LCSM
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @JFreemanDaily: @TimAllenMDJD Yes, need #cancer #clinicaltrial PROs (patient reported outcomes) that measure #QoL (quality of life) that…
Brendon Stiles @BrendonStilesMD
Almost time to wind the chat down. This has been a great discussion. It is always therapeutic for me to see each of you here and to surround myself in this community. #lcsm
#LCSM Chat @lcsmchat
RT @ProjectBreath: T5. Financial toxicity goes beyond health costs - consequential financial hardship impacts on family relationships, cred…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @wi_qiong: @TimAllenMDJD I can't agree more. #QualityOfLife is overlooked. #LCSM @TimAllenMDJD
Eric Bernicker @EricBernicker
@sjwhitlock And are not aware that they are missing out on key information #LCSM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Almost time to wind the chat down. This has been a great discussion. It is always therapeutic for me to see each of…
Brendon Stiles @BrendonStilesMD
This is shocking indeed. #lcsm
Janet Freeman-Daily @JFreemanDaily
@n8pennell I'd love to see the money that's currently spent on creating new "get biomarker testing!" websites applied to increasing provider education on the ground. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @jillfeldman4: T5 Collaborate with community hospitals and minority physicians – physicians are a trusted voice in the community and pe…
Jill Feldman @jillfeldman4
T5 What's upsetting is that all the advancements in treatment & the hope many of feel MEAN NOTHING to approx 80% of people with #lungcancer because of disparities Everyone below the water in this graph! #LCSM https://t.co/B3nYNnsnUq
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @n8pennell I'd love to see the money that's currently spent on creating new "get biomarker testing!" websites applied to…
#LCSM Chat @lcsmchat
RT @jillfeldman4: T5 What's upsetting is that all the advancements in treatment & the hope many of feel MEAN NOTHING to approx 80% of peopl…
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @jillfeldman4: T5 What's upsetting is that all the advancements in treatment & the hope many of feel MEAN NOTHING to approx 80% of peopl…
Stephen Kearney @s_j_kearney
RT @bjork5: Big issue. I don’t have the answer, but every lung cancer patient deserves access to genomic testing and latests treatments, ac…
Lillian Leigh @ProjectBreath
@BrendonStilesMD Ditto! Thanks @BrendonStilesMD! #LCSM
Sue McCullough @SueMcCu30398663
#LCSM Money collected in smoker's tax, spent on research and treatment or get the manufacturers to pay.
Brendon Stiles @BrendonStilesMD
Great recap of #WCLC20 #LungCancer here in case you missed it. #lcsm @StephenVLiu @NarjustDumaMD: https://t.co/xqRNI2ZpZT
LungCancer.net @LungCancer_HU
RT @JFreemanDaily: T5. To address disparities in access to #lungcancer care, need to have ALL the players at the table: patients, disadvan…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Great recap of #WCLC20 #LungCancer here in case you missed it. #lcsm @StephenVLiu @NarjustDumaMD: https://t.co/xqRNI2…
Sue McCullough @SueMcCu30398663
#LCSM Oops should have put T5
Brendon Stiles @BrendonStilesMD
Please share your closing thoughts! #lcsm
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
RT @BrendonStilesMD: Great recap of #WCLC20 #LungCancer here in case you missed it. #lcsm @StephenVLiu @NarjustDumaMD: https://t.co/xqRNI2…
Jill Feldman @jillfeldman4
T5 JUSTICE #LCSM #healthequity https://t.co/MBj4opWCTD
Linnea Olson @1111linno
T5 We need to recognize that this group is like a Salon. We are not representative. Our very presence here speaks of privilege. #lcsm
Dr. Amy C. Moore @acmoorephd
@GO2Foundation is "targeting" strategies to improve uptake of comprehensive #biomarker testing across our national network of Centers of Excellence #lcsm
Kim Moran-MacIntosh 🇨🇦 🍀 @Kamacintosh
@BrendonStilesMD Ty this was enlightening and informative #lcsm
#LCSM Chat @lcsmchat
RT @1111linno: T5 We need to recognize that this group is like a Salon. We are not representative. Our very presence here speaks of privile…
#LCSM Chat @lcsmchat
RT @acmoorephd: @GO2Foundation is "targeting" strategies to improve uptake of comprehensive #biomarker testing across our national network…
Linnea Olson @1111linno
T5 And yet we must represent. In order to do so, we have to ask lots of questions. Be observant. And always humble. #lcsm
Sara Whitlock @sjwhitlock
I think about this ALL the time. #LCSM
Brendon Stiles @BrendonStilesMD
I would have loved to have spent time with all of you in Singapore! #lcsm #wclc20 Virtual conferences are more accessible and allow broader particpation, but I miss the face to face. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @TimAllenMDJD: Walk the talk. #lcsm https://t.co/6FXwLAgEZd
#LCSM Chat @lcsmchat
Thank you @BrendonStilesMD for moderating tonight. We appreciate you! #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. #COVID19 has certainly also affected access to care. #lcsm From @LauraMezquitaMD: https://t.co/Kkcq8PUUm9
#LCSM Chat @lcsmchat
RT @1111linno: T5 And yet we must represent. In order to do so, we have to ask lots of questions. Be observant. And always humble. #lcsm
Dr Riyaz Shah @DrRiyazShah
@BrendonStilesMD keep safe, get vaccinated and lets meet..?ESMO21? #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @bjork5: Big issue. I don’t have the answer, but every lung cancer patient deserves access to genomic testing and latests treatments, ac…
Brendon Stiles @BrendonStilesMD
Hoping #WCLC21 or #WCLC22 is in person. If so, find me. Drinks on me! Would love to talk to each of you. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @sjwhitlock: I talk to a lot of newly diagnosed people. Shocked at how many have not had bio marker testing. #lcsm https://t.co/Jk7BrsUy…
Janet Freeman-Daily @JFreemanDaily
RT @ProjectBreath: T5. Financial toxicity goes beyond health costs - consequential financial hardship impacts on family relationships, cred…
Brendon Stiles @BrendonStilesMD
RT @DrRiyazShah: @BrendonStilesMD keep safe, get vaccinated and lets meet..?ESMO21? #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @Kamacintosh: @BrendonStilesMD @LauraMezquitaMD Delays and fear of going to hospital / can’t assess a patient by phone #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: Almost time to wind the chat down. This has been a great discussion. It is always therapeutic for me to see each of…
Janet Freeman-Daily @JFreemanDaily
RT @EricBernicker: @sjwhitlock And are not aware that they are missing out on key information #LCSM
Brendon Stiles @BrendonStilesMD
RT @acmoorephd: @GO2Foundation is "targeting" strategies to improve uptake of comprehensive #biomarker testing across our national network…
Janet Freeman-Daily @JFreemanDaily
RT @jillfeldman4: T5 What's upsetting is that all the advancements in treatment & the hope many of feel MEAN NOTHING to approx 80% of peopl…
Denise A Croix, PhD @CroixDenise
@BrendonStilesMD Thank you for a very informative discussion! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: Great recap of #WCLC20 #LungCancer here in case you missed it. #lcsm @StephenVLiu @NarjustDumaMD: https://t.co/xqRNI2…
Lillian Leigh @ProjectBreath
Unless we do our part to reduce inequities, we play a part in perpetuating them. #LCSM https://t.co/bF7nMPMq3m
Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD
Yes, many thanks @BrendonStilesMD for moderating this excellent #lcsm twitterchat. It was a privilege to participate.
Janet Freeman-Daily @JFreemanDaily
RT @jillfeldman4: T5 JUSTICE #LCSM #healthequity https://t.co/MBj4opWCTD
benjamin wu @benjaminwumd
RT @BrendonStilesMD: T3. Also intriguing, was the presentation on germline mutations in #SCLC. Iz this a heritable disease? https://t.co…
Jill Feldman @jillfeldman4
T5 Let's all take a pledge & commit to self-reflection, to acknowledging disparities exist, funding minority scientists, embedding a ‘health equity’ lens into all initiatives and programs, advocating for antiracism and to prioritize people over profits. #LCSM
Narjust Duma, M.D. @NarjustDumaMD
RT @BrendonStilesMD: #LungCancer led the way with newsworthy presentations. Great summary here from @StephenVLiu @NarjustDumaMD and Ross S…
#LCSM Chat @lcsmchat
RT @ProjectBreath: Unless we do our part to reduce inequities, we play a part in perpetuating them. #LCSM https://t.co/bF7nMPMq3m
Dr. Amy C. Moore @acmoorephd
Also, how do we expand early detection? Not just LDCT screening but how do we effectively address incidental findings too? @GO2Foundation is also working to address this opportunity in our Centers of Excellence.
Janet Freeman-Daily @JFreemanDaily
RT @1111linno: T5 We need to recognize that this group is like a Salon. We are not representative. Our very presence here speaks of privile…
#LCSM Chat @lcsmchat
RT @jillfeldman4: T5 Let's all take a pledge & commit to self-reflection, to acknowledging disparities exist, funding minority scientists,…
Brendon Stiles @BrendonStilesMD
I am even buying for #RadOnc! I even miss them! Desperately! #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @acmoorephd: @GO2Foundation is "targeting" strategies to improve uptake of comprehensive #biomarker testing across our national network…
Janet Freeman-Daily @JFreemanDaily
RT @1111linno: T5 And yet we must represent. In order to do so, we have to ask lots of questions. Be observant. And always humble. #lcsm
Matthew Smeltzer @MattSmeltzer
Good to hear from everyone, so much recent progress, yet so much more needed! #LCSM @lcsmchat
Brendon Stiles @BrendonStilesMD
@acmoorephd @GO2Foundation Let's talk about incidental nodules! I have big plans and need your help. #lcsm
Sue McCullough @SueMcCu30398663
#LCSM Just a big thank you for all your passion.🫁
Dr. Amy C. Moore @acmoorephd
RT @JFreemanDaily: T4: We need to remove barriers to #clinicaltrial participation to achieve #equity in enrollment--need to eliminate dispa…
Gia Sonata @RedGia
@BrendonStilesMD T5 - Many cancer ctrs have finance offices to find programs/charities to assist w/medical bills but often they just send the documents, which require add'l docs & we are OVERWHELMED! Would be nice to augment these offices w/volunteers/interns to help pts complete docs. #LCSM
Donna Malmberg @Seaqueen58
RT @1111linno: T4 I had to pay out of pocket costs today for drug to combat side effects of clinical trial drug. Why would sponsor not pick…
mimiprovenzano @MimiProvenzano
RT @BrendonStilesMD: @acmoorephd